Cochrane Library

Cochrane Database of Systematic Reviews

Topical silver for preventing wound infection (Review)

Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H

Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H.
Topical silver for preventing wound infection.
Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD006478.
DOI: 10.1002/14651858.CD006478.pub2.

www.cochranelibrary.com

WILEY

TABLE OF CONTENTS

HEADER 1
ABSTRACT 1
PLAIN LANGUAGE SUMMARY 2
BACKGROUND 3
OBJECTIVES 3
METHODS 3
RESULTS 5
Figure 1. 6
Figure 2. 8
Figure 3. 9
Figure 4. 11
DISCUSSION 20
AUTHORS' CONCLUSIONS 21
ACKNOWLEDGEMENTS 21
REFERENCES 22
CHARACTERISTICS OF STUDIES 27
DATA AND ANALYSES 55
Analysis 1.1. Comparison 1 Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®), Outcome 1 Number of patients that developed wound infection. 55
Analysis 1.2. Comparison 1 Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®), Outcome 2 Mean pain scores. 55
Analysis 1.3. Comparison 1 Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®), Outcome 3 Costs based on hospital charges (US dollars). 56
Analysis 2.1. Comparison 2 SSD cream (1%) vs biosynthetic dressing with skin substitute (Transcyte® on Biobrane® mesh), Outcome 1 Number of patients that developed wound infection. 56
Analysis 3.1. Comparison 3 SSD cream (1%) with chlorhexidine-impregnated gauze (Bactigras®) vs hydrocolloid (Duoderm® Hydroactive), Outcome 1 Number of patients that developed wound infection. 57
Analysis 4.1. Comparison 4 SSD cream (1%) vs hydrocolloid (Duoderm® Hydroactive), Outcome 1 Number of patients that developed wound infection. 57
Analysis 4.2. Comparison 4 SSD cream (1%) vs hydrocolloid (Duoderm® Hydroactive), Outcome 2 Mean pain scores. 57
Analysis 5.1. Comparison 5 SSD cream (1%) vs honey, Outcome 1 Number of patients with clinical evidence of wound infection. 58
Analysis 5.2. Comparison 5 SSD cream (1%) vs honey, Outcome 2 Number of wounds completely healed. 59
Analysis 5.3. Comparison 5 SSD cream (1%) vs honey, Outcome 3 Number of patients with clinical evidence of wound healing (day 21). 59
Analysis 5.4. Comparison 5 SSD cream (1%) vs honey, Outcome 4 Number of patients reporting free of pain. 59
Analysis 6.1. Comparison 6 SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine, Outcome 1 Number of patients that developed wound infection. 60
Analysis 6.2. Comparison 6 SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine, Outcome 2 Number of patients with adverse effects. 60
Analysis 6.3. Comparison 6 SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine, Outcome 3 Number of patients reporting wound pain. 61
Analysis 7.1. Comparison 7 SSD cream (1%) vs collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®), Outcome 1 Number of patients that developed wound infection. 61
Analysis 7.2. Comparison 7 SSD cream (1%) vs collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®), Outcome 2 Number of patients reporting pain. 61
Analysis 8.1. Comparison 8 SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin), Outcome 1 Number of patients with positive cultures (day 10). 62
Analysis 8.2. Comparison 8 SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin), Outcome 2 Number of wounds completely healed. 62
Analysis 8.3. Comparison 8 SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin), Outcome 3 Number of patients reporting moderate to severe pain. 63
Analysis 9.1. Comparison 9 Nanocrystalline silver-coated dressing (Acticoat®) vs hydrophilic polyurethane dressing (Allevyn®), Outcome 1 Number of patients that developed wound infection. 63

Analysis 9.2. Comparison 9 Nanocrystalline silver-coated dressing (Acticoat®) vs hydrophilic polyurethane dressing (Allevyn®), Outcome 2 Number of wounds healed by day of discharge. 63
Analysis 10.1. Comparison 10 Silver nitrate (0.5%) vs Ringer's lactate, Outcome 1 Number of patients that developed wound infection. 64
Analysis 11.1. Comparison 11 Silver nitrate (0.5%) vs neomycin with bacitracin, Outcome 1 Number of patients that developed wound infection. 64
Analysis 12.1. Comparison 12 SSD/SILVER vs NO SILVER, Outcome 1 Number of patients that developed wound infection. 65
Analysis 13.1. Comparison 13 SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®), Outcome 1 Number of patients that developed wound infection. 66
Analysis 13.2. Comparison 13 SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®), Outcome 2 Mean background pain scores. 66
Analysis 13.3. Comparison 13 SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®), Outcome 3 Mean length of hospital stay. 66
Analysis 14.1. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 1 Number of patients that developed wound infection. 67
Analysis 14.2. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 2 Number of patients with re-epithelialisation within 21 days. 67
Analysis 14.3. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 3 Number of patients reporting adverse effects. 68
Analysis 14.4. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 4 Number of patients using systemic antibiotics. 68
Analysis 14.5. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 5 Total costs of clinical care (USD). 68
Analysis 15.1. Comparison 15 SSD cream (1%) vs synthetic dressing containing silver (Hydron AgSD (1-3%)), Outcome 1 Number of patients with positive cultures. 69
Analysis 16.1. Comparison 16 SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®), Outcome 1 Number of patients that developed wound infection. 69
Analysis 16.2. Comparison 16 SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®), Outcome 2 Number of patients that received antibiotics. 69
Analysis 16.3. Comparison 16 SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®), Outcome 3 Number of patients reporting extreme pain at application. 70
Analysis 17.1. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 1 Sepsis after 10 days. 70
Analysis 17.2. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 2 Number of patients reporting subjective stinging effect. 71
Analysis 17.3. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 3 Number of patients receiving systemic antibiotics for at least 7 days. 71
Analysis 17.4. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 4 Mean length of hospital stay. 71
Analysis 18.1. Comparison 18 SSD cream (1%) (Silvadene®) vs Dimac containing SSD (Sildimac®), Outcome 1 Number of patients that developed clinical wound sepsis. 72
Analysis 18.2. Comparison 18 SSD cream (1%) (Silvadene®) vs Dimac containing SSD (Sildimac®), Outcome 2 Number of patients reporting local adverse effects. 72
Analysis 19.1. Comparison 19 Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%), Outcome 1 Number of patients that developed wound infection. 73
Analysis 19.2. Comparison 19 Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%), Outcome 2 Number of patients that developed bacteraemia. 73
Analysis 19.3. Comparison 19 Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%), Outcome 3 Mean overall painscore. 73
Analysis 20.1. Comparison 20 SSD cream (1%) vs bacitracin zinc ointment, Outcome 1 Number of patients that developed wound infection. 74
Analysis 21.1. Comparison 21 SSD cream (1%) vs neomycin sulfate, Outcome 1 Number of patients that developed wound infection. 74
Analysis 22.1. Comparison 22 SSD cream (1%) vs petrolatum, Outcome 1 Number of patients that developed wound infection. 75
Analysis 23.1. Comparison 23 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze, Outcome 1 Number of patients that developed wound infection. 75

Analysis 23.2. Comparison 23 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze, Outcome 2 Number of wounds completely healed at end of treatment. 76
Analysis 23.3. Comparison 23 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze, Outcome 3 Number of patients that reported adverse effects. 76
Analysis 24.1. Comparison 24 SSD cream (1%) vs benzoic acid, salicylic acid and Quercus rubra extract (Bensal HP), Outcome 1 Number of wounds healed (6 weeks). 76
Analysis 25.1. Comparison 25 Activated-charcoal dressing containing silver (Actisorb Plus®) vs conventional phase-adapted therapy using diverse topical modalities, Outcome 1 Number of wounds healed (6 weeks). 77
Analysis 26.1. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 1 Number of patients that developed wound infection. 78
Analysis 26.2. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 2 Time to complete healing. 78
Analysis 26.3. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 3 Number of wounds completely healed during study. 78
Analysis 26.4. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 4 Percentage ulcer area reduction in 8 weeks. 78
Analysis 26.5. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 5 Ulcer depth reduction in 8 weeks (cm). 79
Analysis 26.6. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 6 Number of patients that experienced adverse effects. 79
Analysis 27.1. Comparison 27 SSD cream (1%)/hydrocolloid vs hydrocolloid, Outcome 1 Number of patients that developed wound infection. 79
Analysis 28.1. Comparison 28 SSD cream (1%)/hydrocolloid vs non-occlusive paraffin-impregnated gauze, Outcome 1 Number of patients that developed wound infection. 80
APPENDICES 80
HISTORY 85
CONTRIBUTIONS OF AUTHORS 85
DECLARATIONS OF INTEREST 86
SOURCES OF SUPPORT 86
DIFFERENCES BETWEEN PROTOCOL AND REVIEW 86
INDEX TERMS 86

[Intervention Review]

Topical silver for preventing wound infection

Marja N Storm-Versloot[1], Cornelis G Vos[1], Dirk T Ubbink[2], Hester Vermeulen[2]

[1]Department of Surgery, Academic Medical Centre at the University of Amsterdam, Amsterdam, Netherlands. [2]Quality Assurance & Process Innovation, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands

Contact address: Marja N Storm-Versloot, Department of Surgery, Academic Medical Centre at the University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands. m.n.storm@amc.uva.nl.

Editorial group: Cochrane Wounds Group.
Publication status and date: New, published in Issue 3, 2010.

Citation: Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. *Cochrane Database of Systematic Reviews* 2010, Issue 3. Art. No.: CD006478. DOI: 10.1002/14651858.CD006478.pub2.

ABSTRACT

Background

Silver-containing treatments are popular and used in wound treatments to combat a broad spectrum of pathogens, but evidence of their effectiveness in preventing wound infection or promoting healing is lacking.

Objectives

To establish the effects of silver-containing wound dressings and topical agents in preventing wound infection and healing of wounds.

Search methods

We searched the Cochrane Wounds Group Specialised Register (6 May 2009); The Cochrane Central Register of Controlled Trials (CENTRAL) (2009 Issue 2); Ovid MEDLINE (1950 to April Week 4 2009); Ovid EMBASE (1980 to 2009 Week 18); EBSCO CINAHL (1982 to April Week 4 2009) and Digital Dissertations (to May 2009) for relevant trials. We contacted manufacturers and distributors.

Selection criteria

Randomised controlled trials (RCTs) comparing silver-containing wound dressings and topical agents with silver-containing and non silver-containing comparators on uninfected wounds.

Data collection and analysis

Two authors independently selected trials, assessed risk of bias, and extracted data.

Main results

We identified 26 RCTs (2066 patients). Heterogeneity of treatments and outcomes precluded meta-analysis. We grouped results according to wound type, and silver preparation.

Burns

Thirteen trials compared topical silver (in a variety of formulations - including silver sulphadiazine (SSD) cream) with non-silver dressings. One trial showed fewer infections with silver nitrate when compared with a non-silver dressing, but three trials showed significantly more infection with SSD than with the non-silver dressing.

Six trials compared SSD cream with silver-containing dressings. One showed significantly fewer infections with the silver-containing dressing (Hydron AgSD) compared with SSD, the remaining five found no evidence of a difference.

One trial compared two silver-containing dressings, and showed a significantly lower infection rate with silver-coated gauze (Acticoat®) than with silver nitrate gauze.

Other wounds

Six trials compared SSD/silver-containing dressings with non-silver dressings (nine dressings in total). Most comparisons (seven) found no significant differences in infection rates; one trial in a variety of wounds exhibited significantly fewer infections with SSD/hydrocolloid, but another, in acute wounds, found significantly more infections with SSD. Only one comparison showed a significant reduction in healing time associated with a silver-containing hydrofibre dressing in diabetic foot ulcers.

Authors' conclusions

There is insufficient evidence to establish whether silver-containing dressings or topical agents promote wound healing or prevent wound infection; some poor quality evidence for SSD suggests the opposite.

PLAIN LANGUAGE SUMMARY

Probable that silver-containing dressings and creams do not prevent wound infection or promote healing

Wound dressings and creams containing silver are widely used. It is thought that silver may help wounds to heal faster and prevent infection, but we did not know if this was true. This review identified 26 trials (involving 2066 participants) comparing silver-containing dressings or creams against dressings or creams that did not contain silver. Twenty of the trials were on burn wounds, while the other trials were on a mixture of wound types. Most studies were small and of poor quality. After examining them all, the authors concluded that there is not enough evidence to support the use of silver-containing dressings or creams, as generally these treatments did not promote wound healing or prevent wound infections. Some evidence from a number of small, poor-quality studies suggested that one silver-containing compound (silver sulphadiazine) has no effect on infection, and actually slows down healing in patients with partial-thickness burns.

BACKGROUND

Description of the condition

Wounds are a prevalent clinical problem and a burden to many patients, resulting in pain, discomfort, longer hospital stay, and considerable economic costs for the healthcare system. Wounds are either acute or chronic, and can result from venous or arterial insufficiency, diabetes, burns, trauma, chronic pressure or surgery (O'Meara 2001; O'Meara 2008). If wounds become contaminated with bacteria or clinically infected, wound healing is likely to be impaired (Ovington 2003). This holds true for both acute and chronic wounds. In addition, wound infection is one of the most common surgical complications (Wilson 2004), and leads to significant mortality and morbidity. The focus in wound care, therefore, is to prevent wound infection and to promote wound healing.

Prevention of wound infection has always been a challenge. It was not until the late eighteenth century that micro-organisms were recognised as the cause of infectious diseases, and the principles of asepsis and hygiene began to be more fully understood (germ theory, as developed by Pasteur during the period 1860 to 1863, and Lister's development of antiseptic surgery) (Abedon 1998). Good hygiene and use of antiseptics were initially considered effective strategies for the prevention of infection, including wound infection. Nurses developed stringent hygiene rules for dressing changes (Arrowsmith 2001; Fernandez 2008; Lethaby 2008; Moore 2005), and physicians experimented with various antiseptics. Some of these preventative actions have been investigated for their effectiveness in various types of wounds, including aseptic dressing techniques (Lawson 2003; Stotts 1997), hand-rubbing (Kac 2005; Moralejo 2003; Rossoff 1995; Rotter 1997; Tanner 2008), sterile gloving (Adeyemo 2005; Perelman 2004), shaving (Balthazar 1982; Tang 2001; Tanner 2006), and skin disinfection (Edwards 2004).

Description of the intervention

Several antiseptic dressings or agents are available, each claiming advantages regarding wound healing or prevention of wound infection. The effectiveness of antiseptics such as povidone iodine, chlorhexidine, alcohol, and silver-based compounds against microorganisms has been studied in vitro as well as in vivo (Brooks 2001; Kucan 1981; Lammers 1990; Nagl 2003; Vogt 2001; Wilson 1986). In particular, silver-based compounds (e.g. silver sulphadiazine cream (SSD)) have been widely used on burns since the 1960s in an attempt to overcome the problem of wound infection (Hartford 1981), and increasingly, silver-containing dressings and topical applications are being used to prevent infection in non-burn wounds such as leg ulcers (Karlsmark 2003), diabetic foot ulcers (Bergin 2006), fingertips (Jakobsen 1993), and pressure ulcers (Dowsett 2004). There is a growing number of silver-containing dressings and topical agents available for the treatment of skin wounds, including creams such as SSD, silver salts such as silver nitrate, alginates (e.g. Silvercel®), foams (e.g. Avance, Contreet Ag), hydrofibres (e.g. Aquacel® Ag), hydrocolloids (e.g. SSD/hydrocolloid, Contreet Ag) and polymeric films and meshes (e.g. Arglaes), including metallic, nanocrystalline (e.g. Acticoat®) or ionic silver (Aquacel® Ag).

How the intervention might work

Silver ions bind to the DNA of bacteria and bacterial spores, thus reducing their ability to replicate (Ballard 2002; Cooper 2004). Furthermore, silver is reported to be effective against all known bacteria, fungi and some viruses (Ovington 2001). Few bacteria have been shown to develop resistance to silver (resistance is a major problem associated with use of antibiotics). Silver has also been described as effective against malodour (Münter 2006). The various silver-containing dressings differ in the way the Ag^+ ions are released. Mostly, Ag^+ ions are released from the dressing through oxidation when the silver atoms come into contact with fluid. The silver can be incorporated as complex silver molecules in creams, ointments, hydrocolloids, hydrogels or foam dressings, which regulate the speed of delivery. Recent products have been produced in an attempt to ensure a more controlled and prolonged release of small (nanocrystalline) silver particles into the wound area. This nanocrystalline form releases silver ions faster than the normal silver materials, and, therefore, is claimed to have increased antimicrobial activity (Dunn 2004).

Why it is important to do this review

Silver-containing dressings have become popular despite the absence of a robust summary of the evidence for their role in preventing wound infection, and encouraging wound healing (Brett 2006). The effect of silver-containing wound dressings and topical applications as treatments for infected wounds is the subject of a related review (Vermeulen 2007), which identified little evidence of effectiveness. It is timely, therefore, to conduct a systematic review of the effects of silver-containing dressings and topical agents for the prevention of wound infection and the promotion of wound healing in uninfected wounds.

OBJECTIVES

To summarise the evidence for the effects of silver-containing dressings and topical agents compared with non-silver dressings and topical agents in terms of preventing of wound infections and/or promoting wound healing.

METHODS

Criteria for considering studies for this review

Types of studies

We considered all randomised controlled trials (RCTs), both published and unpublished, that evaluated the effects of silver-containing dressings and topical agents (used alone or in combination with other dressings/agents), in preventing infection or promoting the healing, or both, of uninfected wounds of any aetiology (cause) and in any care setting.

Types of participants

Men and women aged 18 years and over with any type of wound (not diagnosed as infected at baseline) in any care setting.

Types of interventions

Wound dressings and topical applications containing silver.

Eligible comparisons were:

1. topical silver-containing agents compared with topical agents without silver;
2. dressings containing silver compared with any dressings without silver (including dressings containing other antiseptics);

3. comparisons between alternative topical preparations of silver (e.g. SSD cream);
4. comparisons between alternative silver-containing dressings, including dose comparisons.

Types of outcome measures

Primary outcomes

1. Wound infection rate (Cutting 2005; Mangram 1999; McLaws 2000): infection was defined as localised pain and swelling, spreading erythema (redness), appearance of a purulent exudate, odour, and the presence of a positive bacterial culture with more than 10^5 colony-forming units per mm^3 tissue (Mangram 1999). Trial authors' definitions of infection (e.g. critical colonisation) were also accepted.
2. Wound healing: this was measured as time to complete healing, rate of change in wound area or volume, or both, or time to skin grafting.

We decided to promote the outcome of wound healing from a secondary to a primary outcome after publication of the review protocol, since it is the most important outcome for patients.

The outcome of time to skin grafting was also added post-protocol. Although the appropriateness of a wound for skin graft is a subjective judgement, skin grafting is only undertaken on clean and granulating wounds. We judged these post-protocol changes to be unlikely to introduce bias to the review.

Secondary outcomes

- Adverse events;
- rate of use of systemic antibiotics;
- pain;
- patient satisfaction;
- health related quality of life (HRQoL);
- length of hospital stay (LOS);
- costs.

Search methods for identification of studies

Electronic searches

The following electronic databases were searched:

1. Cochrane Wounds Group Specialised Register (Searched 6 May 2009);
2. The Cochrane Central Register of Controlled Trials (CENTRAL) (*The Cochrane Library* Issue 2, 2009);
3. Ovid MEDLINE (1950 to April Week 4 2009);
4. Ovid EMBASE (1980 to 2009 Week 18);
5. EBSCO CINAHL (1982 to April Week 4 2009);
6. Digital dissertations at http://www.umi.com (to October 2008).

The following search strategy was used in the Cochrane Central Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Wound Infection explode all trees
#2 (wound* NEAR/5 infect*):ti,ab,kw
#3 (#1 OR #2)
#4 MeSH descriptor Skin Ulcer explode all trees
#5 MeSH descriptor Diabetic Foot explode all trees
#6 MeSH descriptor Pressure Ulcer explode all trees
#7 MeSH descriptor Wounds, Penetrating explode all trees
#8 MeSH descriptor Lacerations explode all trees
#9 MeSH descriptor Burns explode all trees
#10 MeSH descriptor Bites and Stings explode all trees
#11 MeSH descriptor Surgical Wound Dehiscence explode all trees
#12 MeSH descriptor Wound Healing explode all trees
#13 (skin NEXT ulcer*) or (foot NEXT ulcer*) or (feet NEAR/5 ulcer*) or (diabetic NEXT foot) or (diabetic NEXT ulcer*) or (leg NEXT ulcer*) or (varicose NEXT ulcer*) or (varicose NEAR/5 wound*) or (venous NEXT ulcer*) or (stasis NEXT ulcer*) or (arterial NEXT ulcer*):ti,ab,kw
#14 ((ischaemic or ischemic) NEXT (wound* or ulcer*)):ti,ab,kw
#15 (bed NEXT sore*) or (pressure NEXT sore*) or (pressure NEXT ulcer*) or (decubitus NEXT ulcer*):ti,ab,kw
#16 (surgical NEXT wound*):ti,ab,kw
#17 ("gun" or guns or gunshot):ti,ab,kw
#18 ("stab" or stabs or stabbing):ti,ab,kw
#19 (burn or burns or scald*):ti,ab,kw
#20 (bite or bites or biting):ti,ab,kw
#21 laceration*:ti,ab,kw
#22 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (infect* or swell* or swollen or erythema* or odour or odor or hypertherm* or coloni* or contamin* or inflamm* or purulent or exudat* or devital*):ti,ab,kw
#24 (positive NEAR/5 culture*):ti,ab,kw
#25 (pain* NEAR/5 wound*):ti,ab,kw
#26 (dirty NEAR/5 wound*):ti,ab,kw
#27 (#23 OR #24 OR #25 OR #26)
#28 MeSH descriptor Silver explode all trees
#29 MeSH descriptor Silver Sulfadiazine explode all trees
#30 (silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina):ti,ab,kw
#31 (#28 OR #29 OR #30)
#32 (#22 AND #27 AND #31)
#33 (#3 AND #31)
#34 (#32 OR #33)

The Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL search strategies can be found in Appendix 1, Appendix 2 and Appendix 3 respectively. The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying reports of randomised controlled trials in MEDLINE (the sensitivity- and precision-maximising version (2008 revision)) Ovid format (Lefebvre 2008). The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN 2008). No date or language restrictions were applied.

Searching other resources

We also contacted companies, manufacturers and distributors of silver dressings for details of unpublished and ongoing trials and scrutinised citations within all obtained trials and major review articles to identify any additional trials.

Data collection and analysis

Selection of studies

Two review authors (HV and DU) independently assessed the titles and abstracts of studies identified from the search in terms of their relevance and design. Full text versions of articles were obtained if, from the initial assessment, it was suggested they might meet the inclusion criteria. Another review author (either CV or MS) assessed those studies where there was disagreement.

Data extraction and management

Details of selected trials were extracted and summarised using a data extraction sheet. Data from trials published in duplicate were included only once. Data extraction was undertaken by one review author (CV), and checked for accuracy by a second (MS). Any discrepancy was resolved by discussion.

We extracted the following data.

- Characteristics of the trial (method of randomisation, setting, location of care, country, source of funding).
- Participants (number, type of wound(s), definition used to determine infection, wound size, duration of wound, length of follow-up, co-morbidities).
- Intervention (type of silver dressing or topical silver, dose of silver, frequency of dressing changes, co-interventions).
- Comparative intervention (type of dressing or topical application, dose of silver (where applicable), number of dressing changes, co-interventions).
- Primary outcomes: rate of wound infection; wound healing.
- Secondary outcomes: number and proportion of adverse events; rate of use of systemic antibiotics; pain; patient satisfaction; quality of life (QoL); length of hospital stay (LOS), and cost of treatment.

Assessment of risk of bias in included studies

Two review authors (CV and MS) independently assessed the risk of bias of each trial using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). Any disagreement was referred to a third review author (DU) for adjudication.

The following criteria were applied, and graded, as follows:

1. Sequence generation: was the allocation sequence randomly generated? Yes/No/Unclear

2. Allocation concealment: was allocation adequately concealed? Yes/No/Unclear

3. Blinding: was knowledge of the allocated interventions prevented adequately during the study?

- Was the participant blinded to the intervention? Yes/No/Unclear
- Was the care provider blinded to the intervention? Yes/No/Unclear
- Was the outcome assessor blinded to the intervention? Yes/No/Unclear

4. Incomplete outcome data: were incomplete outcome data adequately addressed?

- Was the drop-out rate described and acceptable (i.e. < 20%) Yes/No/Unclear
- Were all randomised participants analysed in the group to which they were allocated? (i.e. using intention-to-treat (ITT) analysis) Yes/No/Unclear

Other sources of potential bias:

- Were the groups similar at baseline for the most important prognostic indicators? Yes/No/Unclear
- Was the trial sponsored by a manufacturer who had a potential interest in the results? Yes/No/Unclear
- Were co-interventions avoided or given to all groups? Yes/No/Unclear

Appendix 4 outlines the criteria on which the judgements were based in detail. We completed the risk of bias table for each eligible study and present an assessment of risk of bias using a 'risk of bias summary figure'. This display of internal validity indicates the weight readers may give the results of each study.

Data synthesis

Quantitative data were entered into RevMan 5 by one review author (CV) and were checked by a second (MS).

Summary estimates of treatment effect (with 95% confidence intervals (CI)) were calculated for each outcome and every comparison. For continuous outcomes, the mean difference (MD) is presented. For dichotomous outcomes, the risk difference (RD) is presented; this is an absolute effect measure that expresses the difference between the experimental and control event rates, and allows calculation of the number needed to treat (NNT). We refrained from a sensitivity analysis because of the lack of replication of comparisons.

Subgroup analysis and investigation of heterogeneity

We conducted prespecified subgroup analyses for different wound types: burns, acute (e.g. surgical), chronic (e.g. ulcers) and mixed wound types.

Where studies evaluated similar interventions in a similar population we assessed statistical heterogeneity using the Chi^2 test and estimated the amount of heterogeneity using I^2. Where pooling seemed appropriate in view of clinical and methodological similarities between studies, we planned to use a fixed-effect model where I^2 was below 25%. We did not intend to pool studies where inter-study heterogeneity was high (I^2 greater than 75%), and we intended to use a random-effects model when I^2 was between 25% and 75% (Higgins 2003). We constructed a funnel plot to test for publication bias (Egger 1997).

RESULTS

Description of studies

Results of the search

The search identified 313 titles of potential relevance. Discrepancy in judgement regarding suitability occurred in approximately 10% of all abstracts, but was resolved after adjudication by a third review author. After the first screening, 59 citations were considered potentially relevant. Full text articles were obtained and screened

by two review authors independently against the inclusion criteria (Figure 1). One ongoing trial (two citations) was identified (Serena 2008) (Characteristics of ongoing studies), and four trials are awaiting assessment (Chen 2006; Hirsch 2008; Li 2006; Wang 2008) (Characteristics of studies awaiting classification).

Figure 1. Flowchart



Trials were excluded if no infection or healing parameters were reported; or if silver-containing agents were not used in one of the treatment arms; if the trials were not RCTs; or if trials were published in abstract form only and no additional information could be retrieved from the trial authors to allow a decision regarding eligibility for inclusion to be made.

Included studies

Twenty-six trials (33 citations) met the inclusion criteria (Characteristics of included studies). All 26 were published between 1980 and 2008. Study sizes ranged from 14 to 465 participants, and a total of 2066 participants were enrolled. The majority of trials (i.e. 21 of the 26 (81%)) included fewer than 80 participants.

Burns were the most frequently studied wound type (20 out of 26 (77%)), and there was substantial variation between trials in the percentage of total body surface area (TBSA) and depth of burn studied (14 trials studied partial-thickness or superficial burns, six studied full-thickness burns). One trial included a range of types of wound (i.e. venous leg ulcers, partial-thickness burns and donor sites) (Hutchinson 1993). The remaining trials included minor soft tissue injuries (Dire 1995), open surgical or traumatic wounds (Jurczak 2007), venous leg ulcers (Wunderlich 1991), and diabetic foot ulcers (Jacobs 2008; Jude 2007).

Around half of the trials (14 out of 26 (54%)) compared 1% silver sulphadiazine (SSD) cream with another topical agent or dressing without silver (Afilalo 1992; Carneiro 2002; Dire 1995; Gerding 1988; Gerding 1990; Hansbrough 1995; Homann 2007; Hutchinson 1993; Jacobs 2008; Mashhood 2006; Noordenbos 1999; Soroff 1994; Subrahmanyam 1998; Wyatt 1990). Six trials (23%) compared 1% SSD with other silver-containing topical agents or dressings such as Acticoat®, Aquacel® Ag, Hydron® AgSD, Sildimac®, SSD-cerium nitrate, and SSD with chlorhexidine digluconate cream (Caruso 2006; De Gracia 2001; Fang 1987; Inman 1984; Miller 1990; Muangman 2006). One trial compared a silver-coated gauze dressing (Acticoat®) with another topical agent or dressing without silver (Innes 2001), and one trial compared a silver-coated gauze dressing (Acticoat®) with 0.5% silver nitrate solution (Tredget 1998). One trial compared an activated charcoal dressing containing silver (Actisorb Plus®) with other topical agents (Wunderlich 1991). Two trials compared a hydrofibre dressing, containing ionic silver (Aquacel®), with other topical agents (Jude 2007; Jurczak 2007). One trial compared a 0.5% silver nitrate solution with two other agents (Livingston 1990).

While most of the trials had two treatment arms, two trials had three treatment arms (Hutchinson 1993; Livingston 1990), and one trial had four treatment arms (Dire 1995).

All but two trials reported infection rates (Mashhood 2006; Soroff 1994), but the definitions of infection varied. Four trials (15%) defined infection as the presence of more than 10^5 organisms per gram of tissue (Inman 1984; Livingston 1990; Miller 1990; Tredget 1998); 15 trials (58%) accepted positive wound swabs or clinical signs of infection as evidence of infection. Seven trials

(27%) provided no definition of infection (Afilalo 1992; Caruso 2006; Gerding 1990; Hansbrough 1995; Noordenbos 1999; Soroff 1994; Wyatt 1990). Twenty-one trials (81%) reported healing rates predominantly in terms of days to complete healing, or time to complete re-epithelialisation.

Pain was the secondary outcome measure most frequently reported. Three trials reported a sample size calculation (Caruso 2006; Jude 2007; Jurczak 2007). It was not clear whether informed consent was obtained in 11 trials, and in 13 trials the ethics review board approval was not reported.

Excluded studies

The Characteristics of excluded studies table provides details of the 18 trials (20 citations) that did not meet the inclusion criteria. Six trials were not RCTs (De Boer 1981; Hadjiiski 1999; Munster 1980; Silver 2007; Stair 1986; Verdú 2004), five trials were only published in abstract form with no further information forthcoming from the study authors (Lanzara 2008; Molnar 2004; Planinsek 2007; Riesinger 2006; Yue Seng 2005), in four trials wounds were already infected (Huang 2007; Jorgensen 2006; Münter 2006; Subrahmanyam 1991). The three remaining trials were excluded because they did not compare dressings (Ganai 2002); no data was reported on the effect of silver (Guilbaud 1993); and the silver compound was not the comparator under investigation rather it was the type of bag covering the hand (Terrill 1991).

Risk of bias in included studies

A summary of the assessment of risk of bias based on the criteria outlined in Higgins 2008 is given in Figure 2 and Figure 3. Additionally, a brief descriptive analysis of the studies is provided below. In general, the overall methodological quality of the included trials was relatively poor, although a few trials were at low risk of bias.

Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.



Figure 2. (Continued)



Figure 3. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.



Allocation

Treatment allocation was reported as random in all included studies, but the method of generating the randomisation sequence was not always clear. Only three trials reported their method of allocation sufficiently clearly to determine that allocation was concealed (Gerding 1988; Gerding 1990; Jurczak 2007).

In sixteen trials the unit of allocation was the individual patient (Afilalo 1992; Carneiro 2002; Caruso 2006; De Gracia 2001; Dire 1995; Hutchinson 1993; Inman 1984; Jacobs 2008; Jude 2007; Jurczak 2007; Livingston 1990; Mashhood 2006; Muangman 2006; Subrahmanyam 1998; Wunderlich 1991; Wyatt 1990), and in the remaining ten trials the unit of allocation was the wound (Fang 1987; Gerding 1988; Gerding 1990; Hansbrough 1995; Homann 2007; Innes 2001; Miller 1990; Noordenbos 1999; Soroff 1994; Tredget 1998).

Blinding

One trial reported double-blinding with regard to the treatment given (Dire 1995), and two trials reported blinding of outcome assessors (Homann 2007; Wyatt 1990). All other trials did not report blinding sufficiently.

Incomplete outcome data

Drop-out rate described and acceptable?

Follow-up was less than 80% in three trials (Afilalo 1992; Hansbrough 1995; Hutchinson 1993), and unclear in two trials (Fang 1987; Inman 1984). In the remaining 21 trials there were either no dropouts, or the proportion of dropouts was less than 20%.

ITT analysis

We defined intention-to-treat (ITT) analysis as occurring when all randomised participants were reported or analysed in the group to which they were allocated for the most important time point of outcome measurement, irrespective of non-compliance and co-interventions**.** Thirteen trials conducted an ITT analysis, but thirteen either did not (Afilalo 1992; Caruso 2006; De Gracia 2001; Dire 1995; Gerding 1988; Gerding 1990; Homann 2007; Inman 1984; Soroff 1994; Wyatt 1990), or it was unclear whether this principle was applied (Fang 1987; Hutchinson 1993; Miller 1990).

Other potential sources of bias

Financial support

Twelve trial groups reported that they had received financial support from one or more companies. One trial reported that it did not received financial support (Noordenbos 1999), while the remaining 13 trials did not report this aspect at all.

Baseline comparability

In 22 trials the treatment groups appeared to be broadly comparable at baseline for wound size, aetiology and duration. Baseline comparability was unclear in one trial (Mashhood 2006), and in the remaining three trials the treatment groups were not comparable at baseline (Inman 1984; Jude 2007; Soroff 1994). In Inman 1984 scald burns were more frequent in the SSD group than in the SSD/chlorhexidine digluconate cream group; no adjustments in the analysis were made to compensate for this imbalance. In the trials Jude 2007 and Soroff 1994 the wound size at baseline seemed different between both groups, although their authors had stated no differences.

Co-interventions

The intervention of interest appeared to be the only systematic difference in the management of treatment groups within 23 of the included trials. In three trials it was unclear whether there was any imbalance in co-interventions delivered (Caruso 2006; Hutchinson 1993; Muangman 2006).

Analysis of time to healing as a continuous variable

It is not appropriate to analyse time-to-event data - such as time to healing - using methods for continuous outcomes (e.g. using mean times-to-event) as the relevant times are only known for the subset of participants who have experienced the event (e.g. healing). The most appropriate way of summarising time-to-event data is to use methods of survival analysis and express the intervention effect as a hazard ratio. A hazard ratio is interpreted in a similar way to a risk ratio, as it describes how many times more (or less) likely a participant is to experience the event at a particular point in time if they receive the experimental rather than the control intervention. Inappropriate analysis of outcome data can introduce bias in the interpretation of the results.

Effects of interventions

Diverse interventions were evaluated in the 26 included trials, and, as a result, pooling was possible for only two trials. We have presented the results according to wound type, i.e. acute wounds (first burns and then other wounds), chronic wounds, and mixed wounds. Within each wound type we investigated the following comparisons:

1. topical silver-containing agents compared with topical agents or dressings without silver (SSD versus no silver);
2. dressings containing silver compared with any dressings without silver (silver versus no silver);
3. comparisons between alternative topical preparations of silver, e.g. SSD cream (SSD versus silver);
4. comparisons between alternative silver-containing dressings including dose comparisons (silver versus silver).

For each outcome and comparison the results are presented below. Trial details are summarised in the Characteristics of included studies.

We were only able to assess the possibility of publication bias for one comparison, SSD/silver versus no silver, where we performed a funnel plot for the outcome of infection rate (Figure 4). The funnel plot included 10 trials with 11 comparisons demonstrating symmetry, indicating no publication bias.

Figure 4. Funnel plot of comparison: 12 SSD/SILVER vs NO SILVER, outcome: 12.1 Number of patients developed wound infection.



1. Acute wounds: burns

1.1 Topical silver-containing agents compared with topical agents without silver (silver sulphadiazine (SSD) versus no silver)

Eleven trials compared a topical application containing silver (1% silver sulphadiazine cream, SSD) with another topical agent or dressing not containing silver. Only two trials compared similar interventions and were pooled (Gerding 1988; Gerding 1990), while the remainder were considered separately.

1.1.1 SSD cream compared with biosynthetic dressing (Biobrane®) (two trials)

Gerding 1988 enrolled 43 patients with 50 acute partial-thickness burns, and Gerding 1990 enrolled 52 patients with 56 acute partial-thickness thermal wounds in two trials comparing 1% SSD cream with a biosynthetic dressing.

Primary outcome: infection rate

Gerding 1988 defined wound infection on clinical grounds in conjunction with semi-quantitative surface swab cultures. In this trial a mixture of paired and unpaired data were presented; seven patients were used as matched controls by randomising the paired wounds to treatment with opposite modalities. Gerding 1990 defined wound infection on clinical grounds, but did not give a detailed description. In Gerding 1988 4/23 wounds in the SSD group, and 4/27 in the biosynthetic dressing group were judged to be infected. While in Gerding 1990, 2/26 wounds in the SSD group and 3/30 in the biosynthetic dressing group were judged to be infected. Pooling these two trials (I^2 = 0%) using a fixed-effect model showed no statistically significant difference between groups (RD 0.00; 95% CI -0.12 to 0.12) (Analysis 1.1).

Primary outcome: wound healing rate

Both Gerding trials reported the standard error of the mean; the standard deviation (SD) was calculated for our analysis. In both trials, healing was defined as complete re-epithelialisation. Gerding 1988 reported the mean time to complete healing as 21.3 days (SD 11.03) in the SSD group, and 13.7 days (SD 6.75) in the biosynthetic dressing group, while Gerding 1990 reported the mean time to complete healing as 15.0 days (SD 6.12) in the SSD group and 10.6 days (SD 4.38) in the biosynthetic dressing group. Both trials reported a statistically significant difference in favour of the biosynthetic dressing, however, these original trials analysed time to healing (a time-to-event outcome) as a continuous variable, which is inappropriate and potentially misleading (since it cannot take account of people who did not heal). We did not have access to the original data and therefore could not re-analyse it.

Secondary outcome: pain

Both trials measured pain on a scale from one (none) to five (severe). The pain score was statistically significantly lower in the biosynthetic dressing groups (pooled, fixed-effect, MD 1.41; 95% CI 0.99 to 1.83). Both trials reported standard error of the mean, we calculated the SD for the purposes of analysis (Analysis 1.2).

Secondary outcome: costs

Gerding 1988 reported no statistically significant differences in the mean material costs, based on the total cost of topical cream, dressing materials and medications used in each case. Nursing costs were $238 in the SSD group and $71 in the biosynthetic dressing group (P value < 0.001). No SDs were reported; therefore no mean difference could be calculated. Gerding 1990 reported that mean costs, based on hospital charges, were significantly lower in the biosynthetic dressing group (MD 70; 95% CI 15.5 to 124.5) (Analysis 1.3).

1.1.2 SSD cream compared with biosynthetic dressing with human fibroblast skin substitute (Transcyte on Biobrane mesh) (one trial)

Noordenbos 1999 enrolled 14 patients, each with two partial-thickness burns of similar size, and compared SSD cream on one burn with a biosynthetic dressing combined with human fibroblasts on the other.

Primary outcome: infection rate

The trial report defined wound infection as cellulitis. Six of the 14 burns in the SSD group, and none in the biosynthetic dressing group developed cellulitis. The number of burns that developed cellulitis was significantly lower in the biosynthetic dressing group (RD 0.43; 95% CI 0.16 to 0.70). (Analysis 2.1). The number needed to treat (NNT) with biosynthetic dressings was two, in order to prevent one additional patient developing cellulitis.

Primary outcome: wound healing rate

The report defined healing as 90% re-epithelialisation. The mean time to 90% healing in the SSD group was 18.14 days, compared to 11.14 days in the biosynthetic dressing group. The mean time to healing was significantly shorter in the biosynthetic dressing group. Time to healing is a time-to-event outcome, however, the trialists did not analyse it as such and, therefore, this effect estimate may be inaccurate.

1.1.3 SSD cream with chlorhexidine-impregnated gauze (Bactigras®) compared with hydrocolloid dressing (Duoderm® Hydroactive) (one trial)

Afilalo 1992 enrolled 48 patients with partial-thickness burns and compared a layer of SSD cream covered by chlorhexidine-impregnated gauze (Bactigras) with a hydrocolloid dressing (Duoderm Hydroactive).

Primary outcome: infection rate

Wound infection was not defined in this trial, but was based on the unblinded, subjective opinion of the investigator or the plastic surgeon, and, therefore, was subject to bias. One participant out of 24 in the SSD with chlorhexidine-impregnated gauze group developed an infection, and 2/24 in the hydrocolloid dressing group. There was no statistically significant difference in the number of patients that developed a wound infection (RD: -0.04, 95% CI -0.18 to 0.09) (Analysis 3.1).

Primary outcome: wound healing rate

The trialists defined healing as complete re-epithelialisation. The mean time to complete healing was 11.2 days in the SSD with chlorhexidine-impregnated gauze group, and 10.7 days in the hydrocolloid group. There was no statistically significant difference in the mean time to complete healing. Again, this time-to-event outcome had been inappropriately analysed as a continuous variable rather than by survival analysis, and, therefore, was inaccurate.

Secondary outcome: pain

The pain scores at baseline and the second visit (24 hours after the initial visit) were assessed. Pain was measured on a scale from 1 to 10. There was no statistically significant difference in the groups for the median pain score at baseline or at the second visit.

Secondary outcome: patient satisfaction

Overall satisfaction was reported as excellent or satisfactory for all patients, and there was no statistically significant difference between the groups.

1.1.4 SSD cream compared with hydrocolloid dressing (DuoDerm® Hydroactive) (one trial)

Wyatt 1990 enrolled 50 patients with minor, second-degree burn injuries in order to compare the effects of SSD cream with hydrocolloid dressings.

Primary outcome: infection rate

Wound infection was defined on clinical grounds, but how exactly was unclear. None of the patients developed a wound infection (RD 0.00; 95% CI -0.09 to 0.09) (Analysis 4.1).

Primary outcome: wound healing rate

Healing was defined as complete healing. The mean time to complete healing was 15.59 days in the SSD group, and 10.23 days in the hydrocolloid dressing group. The mean time to complete healing was significantly shorter in the hydrocolloid group. Again, this time-to-event outcome was inappropriately analysed as a continuous variable, and is, therefore, inaccurate.

Secondary outcome: pain

Pain was measured on a scale from one (no pain) to 10 (maximum pain). The mean pain score was 2.28 in the SSD group, and 1.09 in the hydrocolloid dressing group. The mean reported pain score was significantly lower in the hydrocolloid group (MD 1.19; 95% CI 0.56 to 1.82) (Analysis 4.2).

1.1.5 SSD cream compared with honey (two trials)

Mashhood 2006 enrolled 50 patients with superficial and partial-thickness burns. Subrahmanyam 1998 enrolled 50 patients with superficial thermal burns. Both compared the effects of SSD cream with pure, unprocessed, undiluted honey. Mashhood 2006 described it as 'traditional medicine honey' and Subrahmanyam 1998 stated only that the honey was obtained from hives.

Primary outcome: infection rate

While Mashhood 2006 defined wound infection on clinical grounds, and via swabs for bacterial density and culture, infection rate was not reported. For Subrahmanyam 1998 wound infection was defined clinically (presence of pus or slough), and by means of bacterial cultures. There was no statistically significant difference between the two groups in this trial with respect to clinical evidence of wound infection in the short term (day 7), but in the longer term (day 21), the honey group demonstrated significantly fewer infections (RD 0.20; 95% CI 0.03 to 0.37) (Analysis 5.1). The NNT with honey was five, in order to prevent one wound infection.

Primary outcome: wound healing rate

In the Mashhood 2006 trial healing was defined as 100% epithelialisation. The number of wounds completely healed was reported after two, four and six weeks' treatment. At the two and four weeks' treatment time-points, the honey group did significantly better. The number of wounds completely healed after two weeks was 5/25 in the SSD group and 13/25 in the honey treated group (RD -0.32; 95% CI -0.57 to -0.07) (Analysis 5.2). The number of wounds completely healed after four weeks was 15/25 in the SSD group and 25/25 in the honey treated group (RD -0.40; 95% CI -0.60 to -0.20). The NNT with honey was three, in order to promote the healing of one extra wound. All wounds were completely healed after six weeks.

In the Subrahmanyam 1998 trial healing was defined as "patients with clinical and histological evidence of epithelialisation". The number of patients with clinical evidence of wound healing was reported on days 21 and 30, with histological evidence of wound healing reported for days 7 and 21. There was no statistically significant difference between the two groups for the clinical evidence on day 30. For the other time points, the honey group performed significantly better than the SSD group. The number of patients with clinical evidence of wound healing on day 21 was 21/25 in the SSD group and 25/25 in the honey group (RD -0.16; 95% CI -0.31 to -0.01) (Analysis 5.3). The NNT with honey was six, in order to promote the healing of one extra wound.

Secondary outcome: pain

Mashhood 2006 reported pain on the basis of the number of participants who were free of pain after one, two, three and four weeks of treatment. While there was no statistically significant difference between the two groups at the start and end of the trial (i.e. weeks 1 and 4), there was a statistically significant difference between groups in the middle (i.e. weeks 2 and 3), with more patients free of pain in the honey group (RD -0.36; 95% CI -0.61 to -0.11) (Analysis 5.4). We calculated the Mann-Whitney U test: z = -2.823, P value = 0.005.

Secondary outcome: costs

Mashhood 2006 reported the cost of dressing material for one percent of body surface area burnt. The cost of dressing material for each percent of body surface area burnt was PKR 0.10/2 g for SSD, and PKR 0.75/5 ml for honey. No SDs were reported, so no mean difference could be calculated.

1.1.6 SSD cream compared with liposome hydrogel containing polyvinyl-pyrrolidone iodine (PVP-I) (one trial)

Homann 2007 enrolled 47 patients with 94 partial-thickness burns (degree IIa).

Primary outcome: infection rate

Wound infection was defined using clinical criteria such as inflammation. When wound infection was suspected, wound swabs were taken for microbiological investigation. None of the patients developed a wound infection (RD 0.00; 95% CI -0.04 to 0.04) (Analysis 6.1).

Primary outcome: wound healing rate

Healing was defined as 95% to 100% re-epithelialisation. There was no statistically significant difference in the mean time to complete healing (11.3 days for the SSD group, 9.9 days for the liposome hydrogel containing polyvinyl-pyrrolidone iodine (PVP-I) group). Again, this time-to-event outcome was inappropriately analysed as a continuous variable rather than by means of survival analysis.

Secondary outcome: adverse events

There was no statistically significant difference between the groups with respect to wound necrosis and wound itching (RD 0.02; 95% CI -0.05 to 0.10) (Analysis 6.2).

Secondary outcome: pain

Pain was measured, but the method the trialists used was not reported. There was no statistically significant difference in the number of patients reporting wound pain (RD -0.02; 95% CI -0.16 to 0.12) (Analysis 6.3).

1.1.7 SSD cream compared with collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®) (two trials)

Soroff 1994 enrolled 15 patients with 30 partial-thickness burns. Hansbrough 1995 enrolled 79 patients with 158 partial-thickness burns.

Primary outcome: infection rate

Soroff 1994 did not report infection rate. Hansbrough 1995 did not define wound infection, but the number of patients with cellulitis were reported. There was no statistically significant difference in the number of patients who developed cellulitis between the groups (11/79 in the SSD group; 12/79 in the collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®) group), (RD -0.01; 95% CI -0.12 to 0.10) (Analysis 7.1).

Primary outcome: wound healing rate

Soroff 1994 defined healing as complete re-epithelialisation and time to a clean wound bed (determined by the disappearance of injured dermis), while Hansbrough 1995 defined healing as complete re-epithelialisation and time to a clean wound bed (determined by the absence of retained dermis). In both trials, healing was significantly better in the Santyl® group. In Soroff 1994 the median time to complete epithelialisation was 15 days in the SSD group and 10 days in the Santyl® group (P value 0.00007). In the Hansbrough 1995 trial, the mean time to epithelial closure was 22.1 days in the SSD group, and 19.0 days in the Santyl® group (no SD was reported) (P value < 0.001). Again, this time-to-event outcome was inappropriately analysed as a continuous variable.

Secondary outcome: pain and adverse events

Hansbrough 1995 reported pain as an adverse event and described it as burning or stinging. The number of patients reporting pain was significantly lower in the SSD group (RD -0.19; 95% CI -0.31 to -0.07) (Analysis 7.2). The NNT with SSD was five, in order to prevent one patient from experiencing pain. Soroff 1994 reported three patients who described a burning sensation at the wound site in the Santyl® group.

1.1.8 SSD cream/chlorhexidine (Silverex) compared with diphenyldantoin (Phenytoin) (one trial)

Carneiro 2002 enrolled 64 patients with second degree burns.

Primary outcome:infection rate

Bacterial cultures were obtained on days 5 and 10. Negative cultures were defined as the absence of pathogens. The number

of positive bacterial cultures on both days was significantly lower in the diphenyldantoin group. At day 10 15/32 cultures were positive in the SSD/chlorhexidine group compared with 3/32 in the diphenyldantoin group (RD 0.38; 95% CI 0.17 to 0.58) (Analysis 8.1).The NNT with diphenyldantoin was three, in order to prevent one additional positive culture.

Primary outcome: wound healing rate

Wound healing was defined as complete healing. There was no statistically significant difference between the groups in the rate of complete healing; 24/32 wounds in the SSD/chlorhexidine group were completely healed, and 29/32 in the diphenyldantoin group (RD -0.16; 95% CI -0.34 to 0.02) (Analysis 8.2).

Secondary outcome: pain

Pain was measured in categories: moderate to severe pain or discomfort; mild; or no pain or discomfort. Statistically significantly more patients reported moderate to severe pain or discomfort in the SSD/chlorhexidine group (17/32), than in the diphenyldantoin group (7/32) (RD 0.31; 95% CI 0.09 to 0.54) (Analysis 8.3).

Secondary outcome: length of hospital stay

The mean length of hospital stay was 16.3 days in the SSD/chlorhexidine group and 14.2 days in the diphenyldantoin group (not statistically significant). No SDs were reported; therefore no mean difference could be calculated.

Summary for burns: SSD versus no silver

Eleven trials compared SSD with a range of non-silver comparators in participants with superficial or partial-thickness burns. Only four of the eleven trials reported adequate sequence generation (Afilalo 1992; Gerding 1988; Gerding 1990; Homann 2007), and only two described allocation concealment (Gerding 1988; Gerding 1990), therefore these trials were generally of at least moderate, (or unknown), risk of bias and the findings should be interpreted with this in mind.

- Infection rate was reported in nine trials. Six trials found no statistically significant differences (Afilalo 1992; Gerding 1988; Gerding 1990; Hansbrough 1995; Homann 2007; Wyatt 1990), and three trials found a statistically significant increase in infection with SSD compared with the non-silver comparators (Carneiro 2002; Noordenbos 1999; Subrahmanyam 1998).
- Time to complete healing was reported in eight trials, though in each trial this had been inappropriately analysed as a continuous variable ("mean time") rather than as a time-to-event outcome. Six trials showed a statistically significant difference in favour of non-silver dressings (Gerding 1988; Gerding 1990; Hansbrough 1995; Noordenbos 1999; Soroff 1994; Wyatt 1990), and two trials showed no differences (Afilalo 1992; Homann 2007), however, these data would be inaccurate if not all the participants were followed to complete healing.
- The proportions of wounds healed and unhealed at specific time points were reported in three trials. Two trials showed a statistically significant difference in favour of non-silver dressings (Mashhood 2006; Subrahmanyam 1998), and one trial showed no difference (Carneiro 2002).
- Pain was reported in eight trials. While one trial showed a statistically significant difference in favour of SSD (Hansbrough 1995), five trials showed a statistically significant difference is favour of non-silver dressings (Carneiro 2002; Gerding 1988; Gerding 1990; Mashhood 2006; Wyatt 1990), and two trials showed no difference (Afilalo 1992; Homann 2007).

1.2 Dressings containing silver compared with any dressings without silver (silver versus no silver)

1.2.1 Nanocrystalline silver coated dressing (Acticoat®) compared with hydrophilic polyurethane dressing (Allevyn®) (one trial)

Innes 2001 enrolled 17 patients, with 18 paired adjacent burn sites, who required a split-thickness skin graft.

Primary outcome: infection rate

Wound infection was defined clinically by criteria such as erythema, induration, purulent discharge, and malodour. Every third day, swabs were taken and were rated as 1 (light growth), 2 (medium growth), or 3 (heavy bacterial growth). There was no statistically significant difference in the number of patients who developed an infection, or in the number of positive cultures at any time point. None of the patients developed a wound infection (RD 0.00; 95% CI -0.11 to 0.11) (Analysis 9.1).

Primary outcome: wound healing rate

Healing was defined as 90% or more re-epithelialisation. Healing was significantly faster in the hydrophilic polyurethane dressing group (Allevyn®) (14.5 days for the nanocrystalline silver coated dressing (Acticoat®) group, and 9.1 days for the Allevyn® group). Again, this time-to-event outcome was inappropriately analysed as a continuous variable. The number of wounds healed by day of discharge showed a statistical significance in favour of Allevyn® (RD -0.69; 95% CI -0.92 to -0.45) (Analysis 9.2). The NNT with Allevyn® was six, in order to promote one additional wound to heal.

Secondary outcome: cost

The mean cost per cm^2 was USD 0.088 in the Acticoat® group and USD 0.059 in the Allevyn® group. No SDs were reported, so no mean difference could be calculated.

1.2.2 Silver nitrate (0.5%) compared with Ringer's lactate (one trial)

Livingston 1990 enrolled 52 patients with burns who required skin grafting. The trial had three treatment groups; silver nitrate (0.5%) (19 participants), Ringer's lactate (15 participants), and neomycin with bacitracin (18 participants).

Primary outcome: infection rate

Wound infection was defined as present when there were more than 10^5 organisms per gram of tissue. The silver nitrate group showed significantly fewer infections (2/19 infections in the silver nitrate group; 8/15 in the Ringer's lactate group) (RD -0.43; 95% CI -0.72 to -0.14) (Analysis 10.1). The NNT with silver nitrate was two, in order to prevent one wound infection. Mean time to development of wound infection was significantly shorter in the Ringer's lactate group (13.7 days in the silver nitrate group, versus 5.5 days in the Ringer's lactate group). Again, the outcome was inappropriately analysed as a continuous variable.

Secondary outcome: length of hospital stay

Length of hospital stay was only reported for subgroups, and was reported as being significantly shorter for patients in the silver nitrate group with wounds covering 20% to 40% TBSA.

1.2.3 Silver nitrate (0.5%) compared with neomycin with bacitracin (one trial)

In the same trial (Livingston 1990), the comparison arm of silver nitrate (0.5%) (19 participants) was compared with the neomycin with bacitracin arm (18 participants).

Primary outcome: infection rate

Wound infection was defined as present when there were more than 10^5 organisms per gram of tissue. There was no statistically significant difference in the number of patients who developed an infection (2/19 in the silver nitrate group and 6/18 in the neomycin with bacitracin group) (RD -0.23; 95% CI -0.49 to 0.03) (Analysis 11.1). Mean time to development of wound infection was significantly shorter in the neomycin with bacitracin group (13.7 days in the silver nitrate group versus 5.5 days in the neomycin with bacitracin group). Again, this time-to-event outcome was inappropriately analysed as a continuous variable.

Secondary outcome: length of hospital stay

Length of hospital stay was only reported for subgroups, and there were no statistically significant differences between them.

Summary for burns: silver versus no silver

Both trials investigated burns requiring skin grafting. Only one of the trials reported adequate sequence generation (Livingston 1990), and neither trial reported adequate allocation concealment.

- Infection rate was reported in both trials with a total of three dressing comparisons. Two comparisons showed no differences (Innes 2001; Livingston 1990), and one comparison showed a statistically significant difference in favour of silver nitrate (Livingston 1990).
- Time to complete healing was reported in one trial (Innes 2001), which showed a statistically significant difference in favour of non-silver dressings however it had been wrongly analysed as a continuous variable (with mean healing time calculated) whereas time to healing is a time-to-event outcome which should be subject to analysis by survival methods.
- The number of wounds healed was reported in one trial (Innes 2001), which showed a statistically significant difference in favour of non-silver dressings.

An overview of the number of patients who developed a wound infection for all trials comparing SSD/silver versus no silver is given in Analysis 12.1. A funnel plot (Figure 4) revealed no evidence of publication bias for wound infection.

1.3 Comparisons between alternative topical preparations of silver, e.g. SSD cream (SSD versus silver)

1.3.1 SSD cream compared with nanocrystalline silver-coated dressing (Acticoat®) (one trial)

Muangman 2006 enrolled 50 patients, with partial-thickness burns.

Primary outcome: infection rate

Wound infection was defined as the presence of erythema, induration, purulent discharge and malodour. There was no statistically significant difference in the number of patients who developed an infection (4/25 in the SSD group; 3/25 in the nanocrystalline silver-coated dressing (Acticoat®) group) (RD 0.04; 95% CI -0.15 to 0.23) (Analysis 13.1).

Secondary outcome: pain

Pain was measured on a visual analogue pain scale from 1 (no pain) to 10 (extreme pain). Background pain, between dressings, was significantly lower in the Acticoat® group (5 in the SSD group, 4 in the Acticoat® group) (MD 1.00; 95% CI 0.64 to 1.36) (Analysis 13.2).

Secondary outcome: length of hospital stay

The mean length of hospital stay was 21 days in both groups (MD 0.00; 95% CI -6.43 to 6.43) (Analysis 13.3).

1.3.2 SSD cream compared with hydrofibre dressing containing ionic silver (Aquacel® Ag) (one trial)

Caruso 2006 enrolled 82 patients, with superficial, mid-dermal or mixed partial-thickness burns.

Primary outcome: infection rate

Wound infection was not defined. There was no statistically significant difference in the number of patients who developed an infection (6/40 in the SSD group; 8/42 in the hydrofibre dressing containing ionic silver (Aquacel® Ag) group) (RD -0.04; 95% CI -0.20 to 0.12) (Analysis 14.1).

Primary outcome: wound healing rate

Healing was defined as either 100% re-epithelialisation, including open areas; less than 1 cm fully re-epithelialised area; or re-epithelialisation less than 100% but to the extent that surgical interventions were not required. There were no differences in healing within 21 days (24/40 in the SSD group; 31/42 in the Aquacel® Ag group) (RD -0.14; 95% CI -0.34 to 0.06) (Analysis 14.2). For the time to complete re-epithelialisation only median values were given: 17 days in the SSD group and 16 days in the Aquacel® Ag group (P value 0.517). No MD could be calculated. The time to complete re-epithelialisation was analyzed using life table methods. Kaplan Meier survival curves for each treatment group were plotted.

Secondary outcome: adverse events

Adverse events were defined as any untoward medical occurrence that was new or worsened during the trial. There were no statistically significant differences between SSD and Aquacel® Ag for adverse events (RD -0.03; 95% CI -0.24 to 0.19) (Analysis 14.3).

Secondary outcome: use of systemic antibiotics

There was no statistically significant difference between groups in the number of patients that used antibiotics (RD -0.04; 95% CI -0.20 to 0.12) (Analysis 14.4).

Secondary outcome: pain

Pain was measured on a visual analogue scale from 1 (no pain) to 10 (extreme pain). The mean pain score per week was 4.77 in the SSD group and 3.63 in the Aquacel® Ag group (P value 0.003). No SDs were reported, so no mean difference could be calculated. Pain was also measured on an observational scale. Patients were able to grade the extent to which the dressings reduced pain from "extremely well" to "not very well at all". Patients reported statistically significantly less pain associated with the Aquacel® Ag dressing (P value 0.002).

Secondary outcome: costs

Different components of costs were measured and combined later to be able to calculate cost effectiveness. For most components no SDs were reported, so no mean difference could be calculated. All costs were expressed as US dollars. There was no statistically significant difference in the mean total costs of clinical care ($1181 for the SSD group and $1040 for the Aquacel® Ag group) (MD $141; 95% CI -216 to 498) (Analysis 14.5). The average cost effectiveness, calculated from the total cost of clinical care, divided by the proportion of patients with full epithelialisation, was $1968 (95% CI $1483 to $2690) in the SSD group and $1409 (95% CI $1050 to $1858) in the Aquacel® Ag group.

1.3.3 SSD cream compared with synthetic dressing containing silver (Hydron-AgSD) (one trial)

Fang 1987 enrolled 27 patients with 54 second degree burns, with areas of similar size and injury matched.

Primary outcome: infection rate

Wound infection was determined by taking swabs for bacterial colonisation and reporting on the number of positive cultures. The time-point(s) at which the swabs were taken was not reported. The number of positive culture swabs was significantly higher in the SSD group (46/98 swabs in the SSD group; 32/98 in the synthetic dressing containing silver (Hydron-AgSD) group) (RD 0.14; 95% CI 0.01 to 0.28) (Analysis 15.1). The NNT with Hydron-AgSD was seven, in order to prevent one positive culture.

Primary outcome: wound healing rate

No definition of healing was reported. Fang 1987 stated that wounds healed equally in both groups, no data were reported to support this statement.

1.3.4 SSD cream (Flamazine®) compared with 1% SSD plus 0.2% chlorhexidine digluconate cream (Silvazine®) (one trial)

Inman 1984 enrolled 121 patients with fresh, full-thickness burns.

Primary outcome: infection rate

Wound infection was defined by clinical criteria such as softening of eschar, erythema, or colour change accompanied with a quantitative culture with 10^5 or more organisms per gram of burn tissue. There was no statistically significant difference between the groups in the number of patients that developed an infection (12/67 in the SSD group; 10/54 in the SSD with chlorhexidine digluconate cream group) (RD -0.01; 95% CI -0.14 to 0.13) (Analysis 16.1).

Secondary outcome: use of systemic antibiotics

There was no statistically significant difference between groups in the use of antibiotics during the in-hospital period (RD 0.10; 95% CI -0.03 to 0.24) (Analysis 16.2).

Secondary outcome: pain

Pain was not defined. There was no statistically significant difference between groups in the number of patients who experienced extreme pain at the time when cream was being applied (RD -0.02; 95% CI -0.07 to 0.03) (Analysis 16.3).

1.3.5 SSD cream compared with SSD cream containing cerium nitrate (SSD-CN) (one trial)

De Gracia 2001 enrolled 60 patients with moderate and severe burns.

Primary outcome: infection rate

In the De Gracia 2001 trial, wound sepsis was defined as wound deterioration with severe inflammation. Wound biopsies were taken and bacterial growth on culture media was reported. De Gracia 2001 found no statistically significant difference between the groups for any infection outcome. The number of patients developing sepsis after ten days was 3/30 in the SSD group and 0/30 in the SSD-cerium nitrate (SSD-CN) group (RD 0.10; 95% CI -0.02 to 0.22) (Analysis 17.1).

Primary outcome: wound healing rate

The De Gracia 2001 trial defined healing as complete re-epithelialisation, or wounds being ready for skin grafting. Re-epithelialisation was categorised into four groups: 'quick' (0 to 14 days), 'moderate' (15 to 21 days), 'slow' (22 to 35 days), and 'very slow' (more than 35 days). We calculated the Chi^2 statistic as 5.233, and the P value as 0.155. There were no statistically significant differences between the groups.

The mean number of days until complete re-epithelialisation was significantly shorter in the SSD-CN nitrate group (25.1 days in the SSD group; 17.2 days in the SSD-CN group). The mean time to readiness to accept a skin graft was significantly shorter in the SSD-CN group (24.6 days in the SSD group (17 participants); 13.6 days in the SSD-CN group (nine participants). Once again, these were time-to-event outcomes that had been inappropriately analysed as continuous data.

Secondary outcome: adverse events

In the De Gracia 2001 trial skin rashes were observed in both groups, but did not differ significantly between the groups. A subjective stinging effect was significantly higher in the SSD-CN group (RD -0.37; 95% CI -0.58 to -0.15) (Analysis 17.2). The NNT with SSD was three, in order to prevent one participant experiencing a stinging effect.

Secondary outcome: use of systemic antibiotics

There was no statistically significant difference between groups in the number of patients who received oral antibiotics for at least seven days (RD -0.03; 95% CI -0.20 to 0.13) (Analysis 17.3).

Secondary outcome: length of hospital stay

There was no statistically significant difference between groups in the mean length of hospital stay (MD 7.4; 95% CI -1.69 to 16.49) (Analysis 17.4).

1.3.6 SSD cream compared with Dimac containing SSD (Sildimac®) (one trial)

Miller 1990 enrolled 59 patients with two separate, comparable, sustained full-thickness burns.

Primary outcome: infection rate

Wound infection was defined as present when there were more than10^5 organisms per gram of tissue. Wound biopsies were obtained before treatment, and every seven days thereafter until

the last day of treatment. Positive cultures were defined as any growth of any organism. Wound infection was based on clinical judgement. There was no statistically significant difference between the groups in the number of patients who developed an infection at any time point. Clinical wound infection occurred in 2/51 patients in the SSD group and 1/51 patients in the Dimac SSD group (RD 0.02; 95% CI -0.05 to 0.09) (Analysis 18.1).

Secondary outcome: adverse events

There was no statistically significant difference between groups in the number of patients reporting local adverse effects (such as burning and stinging) (RD 0.03; 95% CI -0.10 to 0.16) (Analysis 18.2). Six patients reported adverse effects at both the SSD site and the Dimac SSD site.

Summary for burns: SSD versus silver

Two trials investigated partial-thickness burns and four trials full-thickness or severe burns. Only two out of six trial reports described adequate sequence generation (Caruso 2006; Miller 1990), and none described adequate allocation concealment.

- Infection rates were reported in six trials. No statistically significant differences were found in five trials (Caruso 2006; De Gracia 2001; Inman 1984; Miller 1990; Muangman 2006), though one trial showed a statistically significant difference for the number of positive-culture swabs in favour of the synthetic silver dressings (Fang 1987).
- Time to complete healing was reported in two trials. One trial used appropriate analysis methods and showed no statistically significant differences (Caruso 2006), and the second trial analysed a time-to-event outcome (time to complete healing) inappropriately as a continuous variable (De Gracia 2001) and showed a statistical significance in favour of the SSD-cerium nitrate group.
- The number of wounds healed was reported in three trials. None of the trials showed statistically significant differences (Caruso 2006; De Gracia 2001; Fang 1987).
- Pain was reported in three trials. One trial showed no statistically significant differences (Inman 1984), while two trials showed a statistically significant difference in favour of the silver-containing dressings Acticoat® and Aquacel® Ag (Caruso 2006; Muangman 2006).

1.4 Comparisons between alternative silver-containing dressings including dose comparisons (silver versus silver)

1.4.1 Nanocrystalline silver-coated dressing (Acticoat®) compared with fine-mesh gauze with silver nitrate (0.5%) (one trial)

Tredget 1998 enrolled 30 patients with 60 deep partial- and full-thickness burns.

Primary outcome: infection rate

Wound infection was defined as present when there were more than 10^5 organisms per gram of tissue present. Bacteraemia was defined as the presence of the same bacterium isolated from the blood and the burn wound at concentrations of more than 10^5 organisms per gram of tissue. Significantly fewer patients developed a wound infection in the nanocrystalline silver-coated (Acticoat®) group (5/17 in the Acticoat® group; 16/17 in the fine-mesh gauze with silver nitrate group) (RD -0.65; 95% CI -0.89 to -0.40) (Analysis 19.1). The NNT with nanocrystalline silver was two, in order to prevent one infection. There was no statistically significant difference between groups in the number of patients who developed bacteraemia (1/17 in the Acticoat® group and 5/17 fine-mesh gauze with silver nitrate group) (RD -0.24; 95% CI -0.48 to 0.01) (Analysis 19.2).

Primary outcome: wound healing rate

Healing was defined as complete re-epithelialisation; the authors reported there was no difference between the treatments, but no data were reported to support this statement.

Secondary outcome: pain

Pain was measured on a visual analogue scale from 1 (not painful) to 5 (very painful). Only the mean pain score on dressing removal was significantly lower in the Acticoat® group, but not the mean overall pain score (MD -0.28; 95% CI -0.93 to 0.37) (Analysis 19.3).

2. Acute wounds: other wounds

2.1 Topical silver-containing agents compared with topical agents without silver (SSD versus no silver)

Dire 1995 enrolled 465 patients with minor, uncomplicated, soft-tissue wounds requiring sutures into a study that compared three antimicrobial regimens with paraffin-impregnated gauze. Data from 39 enrolled participants were excluded for protocol violations, so only 426 participants were included in the analysis (i.e. not analysed by intention-to-treat). The trial had four treatment groups in which the following numbers of participants completed the trial; SSD cream (99 participants), bacitracin zinc ointment (109 participants), neomycin sulphate (110 participants), and petrolatum (108 participants). We compared each of these antimicrobial alternatives with SSD cream.

Wound infection was defined as any subjective or objective sign or symptom of infection, e.g. fever, erythema, oedema, induration, tenderness, heat, exudate, adenopathy, and lymphangitis. Wounds were classified into one of five categories based upon clinical assessment, ranging from no signs of infection (384 participants), simple stitch abscess (25 participants), surrounding cellulitis (14 participants), accompanying lymphangitis (three participants), and systemic symptoms (no participants).

2.1.1 SSD cream compared with bacitracin zinc ointment

Primary outcome: infection rate

There was no statistically significant difference between groups in the number of patients who developed wound infections (12/99 in the SSD group; 6/109 in the bacitracin zinc group) (RD 0.07; 95% CI -0.01 to 0.14) (Analysis 20.1).

2.1.2 SSD cream compared with neomycin sulphate

Primary outcome: infection rate

Significantly fewer patients developed wound infections in the neomycin sulphate group (12/99 in the SSD group; 5/110 in the neomycin sulphate group) (RD 0.08; 95% CI 0.00 to 0.15) (Analysis 21.1). The NNT with neomycin sulphate was 13, in order to prevent one infection.

2.1.3 SSD cream compared with petrolatum

Primary outcome: infection rate

There was no statistically significant difference between groups in the number of patients who developed wound infections (12/99 in the SSD group; 19/108 in the petrolatum group) (RD -0.05; 95% CI -0.15 to 0.04) (Analysis 22.1).

2.2 Dressings containing silver compared with dressings without silver (silver versus no silver)

2.2.1 Hydrofibre dressing containing ionic silver (Aquacel® Ag) compared with povidone iodine gauze (one trial)

Jurczak 2007 enrolled 67 patients with open surgical wounds or open traumatic wounds all healing by secondary intention to a randomised controlled trial comparing silver-containing hydrofibre (hydrofibre-Ag) with povidone iodine gauze.

Primary outcome: infection rate

Wound infection was defined on clinical criteria such as warmth, redness, increased tenderness, swelling, increased exudate or purulent discharge, and malodour. There was no statistically significant difference in the number of patients who developed a wound infection during the trial period (4/35 in the Aquacel® Ag group; 4/32 in the povidone iodine group) (RD -0.01; 95% CI -0.17 to 0.14) (Analysis 23.1).

Primary outcome: wound healing rate

Healing was defined as epithelialisation, but also reduction in wound area in mm^2, and reduction in wound depth in mm were reported. The mean time to complete healing was 14.1 days in the Aquacel® Ag group and 13.9 days in the povidone iodine group (log-rank test: not statistically significant). There was no statistically significant difference in the number of patients with complete wound healing at two weeks (8/35 in the Aquacel® Ag group; 3/32 in the povidone iodine group) (RD 0.13; 95% CI -0.04 to 0.31) (Analysis 23.2).
The authors stated that the adjusted mean reduction in wound area was 551 mm^2 in the Aquacel® Ag group and 401 mm^2 in the povidone iodine group. The adjusted mean reduction in wound depth was 9 mm in the Aquacel® Ag group and 10 mm in the povidone iodine group. How, and why, the adjustment was made was not reported. The authors stated that both reductions were statistically significant when compared with baseline, but, when compared with each other, no statistically significant difference was found. No SDs were reported; therefore the mean difference could not be calculated.

Secondary outcome: adverse events

Adverse events were defined as any event that occurred during the trial period, e.g. allergy, skin burn, haemorrhage. There was no statistically significant difference between the groups (RD -0.09; 95% CI -0.21 to 0.02) (Analysis 23.3).

Secondary outcome: pain

Pain was measured on a visual analogue scale from 1 (no pain) to 10 (worst pain imaginable). Although no statistically significant differences were found for the pain score at dressing removal and application, the decrease in mean pain score from baseline when the dressings were in place was -0.7 for Aquacel® Ag versus 0 for povidone iodine gauze, though no SD was given. The overall ability to manage pain could be scored as excellent, good, fair or poor. The pain management was evaluated at the final visit (i.e. when the wound was completely healed or at week 2). Overall 70.6% of participants rated pain management as excellent in the Aquacel® Ag group compared with 22.6% in the povidone iodine gauze group. There was a statistically significant difference in the ability to manage pain in favour of the Aquacel® Ag group; P value < 0.001.

Summary for acute *wounds:* SSD/silver versus no silver

One of the two trials reported adequate sequence generation and adequate allocation concealment (Jurczak 2007).

- Infection rate was reported in both trials with a total of four different dressing comparisons. Three comparisons (Dire 1995; Dire 1995; Jurczak 2007) were not statistically significantly different, and one comparison (Dire 1995) showed a statistically significant difference in favour of neomycin sulphate.
- Time to complete healing was reported in one trial (Jurczak 2007), and was not statistically significant.
- The number of wounds healed was reported in one trial (Jurczak 2007), and was not statistically significant.
- Pain was reported in one trial (Jurczak 2007), and showed a statistically significant difference in favour of hydrofibre dressing containing ionic silver.

3. Chronic wounds

3.1 Topical silver-containing agents compared with topical agents without silver (SSD versus no silver)

3.1.1 SSD cream compared with Bensal HP with QRB7 (one trial)

Jacobs 2008 enrolled 40 patients with Wagner grade 1 or 2 diabetic foot ulcers in a trial comparing SSD with Bensal HP with QRB7, which is a mixture of 6% benzoic acid, 3% salicylic acid and 3% extract of Q rubra (an extract of oak (*Quercus rubra)* bark).

Primary outcome: infection rate

Wound infection was defined on the basis of clinical signs (foul odour, exudate, or erythema) and bacterial cultures. None of the treated wounds demonstrated growth of pathogenic bacteria at six weeks.

Primary outcome: wound healing rate

Healing was defined as the percentage reduction in total wound size (derived by adding the individual wound areas for each participant in each group) at two, four and six weeks. Complete healing was not defined. The "collective" wound diameter of the Bensal HP-treated patients had decreased by 72.5%, whereas the collective diameter of the SSD group had reduced by 54.7% (Student t test: P value 0.059).

There was no statistically significant difference in the number of patients with complete wound healing within six weeks (6/20 in the SSD group; 8/20 in the Bensal HP group) (RD -0.10; 95% CI -0.39 to 0.19) (Analysis 24.1).

Secondary outcome: adverse events

None of the patients experienced adverse effects.

3.2 Dressings containing silver compared with non-silver dressings (silver versus no silver)

3.2.1 Activated-charcoal dressing containing silver (Actisorb Plus®) compared with conventional phase-adapted therapy using diverse topical modalities (one trial)

Wunderlich 1991 enrolled 40 patients with venous leg ulcers of whom 38 were followed to study completion.

Primary outcome: infection rate

Every two weeks swabs were taken and were rated as 0 (no bacterial growth), 1 (light bacterial growth), 2 (medium bacterial growth), or 3 (heavy bacterial growth). The authors reported no differences in infection rates, but no actual data were reported.

Primary outcome: wound healing rate

Healing was defined as granulation (on an ordinal scale from 0 to 3), epithelialisation (on an ordinal scale from 0 to 3), and also as the reduction of the mean ulcer area in cm^2. There was no statistically significant difference in the number of patients healed after six weeks of treatment (6/19 patients in the charcoal-silver group; 2/19 patients in the conventional phase-adapted therapy using diverse topical modalities group) (RD 0.21; 95% CI -0.04 to 0.46) (Analysis 25.1).

3.2.2 Hydrofibre dressing containing ionic silver (Aquacel® Ag) compared with calcium alginate dressing (Algosteril®) (one trial)

Jude 2007 enrolled 434 patients with diabetic foot ulcers (Wagner grade 1 and 2). Although, at baseline, the calcium alginate dressing group (Algosteril®) seemed to have larger ulcers, and more patients in the hydrofibre dressing containing ionic silver (Aquacel® Ag) group were receiving antibiotics, the authors stated that the groups were comparable.

Primary outcome: infection rate

Wound infection was defined on the basis of clinical signs and/or bacterial cultures. There was no statistically significant difference in the number of patients who developed wound infection (11/67 in the Aquacel® Ag group; 8/67 in the Algosteril® group) (RD 0.04; 95% CI -0.07 to 0.16) (Analysis 26.1).

Primary outcome: wound healing rate

Healing was defined as complete re-epithelialisation, and as the reduction of the mean ulcer area in percentage and ulcer depth. Healing speed was defined as a weekly reduction in absolute and percentage ulcer area. Only the mean time to complete healing was significantly lower in the Aquacel® Ag group (52.6 days +/- 1.8 days (SD) Aquacel® Ag group; 57.7 days +/- 1.7 days (SD) Algosteril® group) (MD -5.1; 95% CI -5.69 to -4.51) (Analysis 26.2). Time in days to 100% healing was estimated by Kaplan-Meier survival analysis.

The number of patients with complete wound healing within eight weeks was 21/67 in the Aquacel® Ag group and 15/67 in the Algosteril® group (RD 0.09; 95% CI -0.06 to 0.24) (Analysis 26.3). The mean percentage ulcer area reduction by eight weeks was 58.1% in the Aquacel® Ag group and 60.5% in the Algosteril® group (MD -2.4; 95% CI -18.72 to 13.92) (Analysis 26.4). The reduction in mean ulcer depth at eight weeks was 0.25 cm in the Aquacel® Ag group and 0.13 cm in the Algosteril® group (MD 0.12; 95% CI -0.05 to 0.29) (Analysis 26.5).

Secondary outcome: adverse events

Adverse events were not clearly defined. One of the events mentioned was infection. There was no statistically significant difference in the number of patients who experienced adverse effects (25/67 in the Aquacel® Ag group; 26/67 in the Algosteril® group) (RD -0.01; 95% CI -0.18 to 0.15) (Analysis 26.6).

Summary for chronic wounds: SSD/silver versus no silver

Two of the three trials reported adequate sequence generation (Jacobs 2008; Jude 2007), and none adequate allocation concealment.

- Infection rate was reported in three trials (Jacobs 2008; Jude 2007; Wunderlich 1991), and showed no statistically significant differences.
- Time to complete healing was reported in one trial (Jude 2007), and was significantly faster with the silver hydrofibre (Aquacel® Ag) dressing. Time to healing was appropriately analysed using survival analysis.
- The number of wounds healed was reported in all three trials, and showed no statistically significant difference.

4. Mixed wounds

4.1 Topical silver-containing agents compared with topical agents without silver (SSD versus no silver)

Hutchinson 1993 enrolled 292 patients with venous leg ulcers, partial-thickness burns or partial-thickness donor sites. The trial had three treatment groups; SSD cream/hydrocolloid (58 participants), hydrocolloid alone (108 participants), and non-occlusive paraffin impregnated gauze (126 participants). The results are presented comparing SSD cream to each of the comparators.

Wound infection was defined using clinical criteria such as erythema, oedema, pain and purulent discharge.

4.1.1 SSD cream/hydrocolloid compared with hydrocolloid alone (one trial)

Primary outcome: infection rate

There was no statistically significant difference in the number of patients who developed a wound infection (0/58 in the SSD/hydrocolloid group, and 2/108 in the hydrocolloid group) (RD -0.02; 95% CI -0.06 to 0.02) (Analysis 27.1).

4.1.2 SSD cream/hydrocolloid compared with non-occlusive paraffin impregnated gauze

Primary outcome: infection rate

Significantly fewer patients in the SSD/hydrocolloid group developed a wound infection when compared with the non-occlusive paraffin impregnated gauze group (0/58 in the SSD/hydrocolloid group; 7/126 in the non-occlusive paraffin impregnated gauze group) (RD -0.06; 95% CI -0.10 to -0.01) (Analysis 28.1). The NNT with SSD/hydrocolloid was 18, in order to prevent one infection.

Summary for mixed wounds: SSD versus no silver

This trial did not report adequate sequence generation, nor adequate allocation concealment, therefore effect estimates may be biased.

- Infection rate was reported in this trial with a total of two different dressing comparisons. One comparison showed a statistically significant difference in favour of SSD/hydrocolloid, and the other showed no differences.

Summary for all wounds: SSD/silver versus no silver

Infection rate

Infection rates were reported in 17 trials with a total of 21 different dressing comparisons. One comparison showed a statistically significant difference in favour of silver nitrate dressings (Livingston 1990), 15 comparisons showed no differences, and five comparisons using SSD showed a statistically significant difference in favour of non-silver dressings (Carneiro 2002; Dire 1995; Hutchinson 1993; Noordenbos 1999; Subrahmanyam 1998).

Wound healing rate

Time to complete wound healing was reported in eleven trials. One trial showed a statistically significant difference in favour of hydrofibre dressing with ionic silver (Jude 2007), three trials showed no differences (Afilalo 1992; Homann 2007; Jurczak 2007), and seven trials showed a statistically significant difference in favour of non-silver dressings (Gerding 1988; Gerding 1990; Hansbrough 1995; Innes 2001; Noordenbos 1999; Soroff 1994; Wyatt 1990). In most cases, time to complete wound healing was inappropriately regarded as a continuous outcome and the analysis of these outcomes was, therefore, flawed, leading to potentially misleading results.

Eight trials reported the number of wounds completely healed. Five trials showed no differences (Carneiro 2002; Jacobs 2008; Jude 2007; Jurczak 2007; Wunderlich 1991), and three trials showed a statistically significant difference in favour of non-silver dressings(Innes 2001; Mashhood 2006; Subrahmanyam 1998).

Adverse events

Adverse events were reported in four trials. None of them showed statistically significant differences (Homann 2007; Jacobs 2008; Jude 2007; Jurczak 2007).

Pain

Pain was reported in nine trials, but was expressed in different ways, e.g. the need for analgesia, or on a visual analogue scale (VAS). Overall, the reported pain scores were low in the majority of these trials, and the absolute differences in pain scores between the studied interventions were minimal. Two trials showed a statistically significant difference in favour of silver-containing dressings (Hansbrough 1995; Jurczak 2007), two trials found no differences (Afilalo 1992; Homann 2007), and five trials showed a statistically significant difference in favour of non-silver dressings (Carneiro 2002; Gerding 1988; Gerding 1990; Mashhood 2006; Wyatt 1990).

Patient satisfaction

Patient satisfaction was reported in one trial (Afilalo 1992), and showed no statistically significant differences.

Length of hospital stay

Length of hospital stay was reported in two trials, with a total of three dressing comparisons. Only one patient group treated with silver nitrate for burns covering 20% to 40% of the total body surface area experienced significantly shorter hospital stay compared with participants who received Ringer's lactate (Livingston 1990). No statistically significant differences were present for any of the other groups (Livingston 1990), or trial (Carneiro 2002).

Costs

Costs were reported in four trials. One trial (Innes 2001), found that the mean costs per cm^2 of dressing - based on price lists supplied by the manufacturers - were lower in the non-silver dressings group, compared with the silver-containing dressing group. One trial reported costs of dressings per percent of body surface burnt (Mashhood 2006), but differences were not reported. Both of the remaining two trials showed a statistically significant difference in favour of non-silver dressings (Gerding 1988; Gerding 1990).

DISCUSSION

This review highlights the lack of conclusive evidence on the effects of silver-containing dressings or agents to prevent wound infection and to promote wound healing. In particular, there was no evidence to support the use of silver sulphadiazine (SSD) for prevention of wound infection in patients with partial-thickness burns. None of the trials indicated a beneficial effect for SSD for other outcomes when compared with other silver-containing or non-silver dressings. Furthermore, there was evidence that SSD may delay wound healing, may be more expensive, and may be more painful when applied to burns. The few trials on full-thickness burns and acute, chronic, or mixed wounds showed insufficient evidence for a beneficial effect of silver-containing dressings to decrease infection rates and to aid wound healing.

Only one trial showed significantly better results in terms of infection rates when another agent was added to the silver-containing dressing: infection rates were significantly lower than with SSD cream alone when a synthetic dressing was added to silver sulphadiazine cream (Hydron-SSD) (Fang 1987). The nanocrystalline form of silver present in the Hydron-SSD dressing, which releases silver ions faster, might explain the better results in burns. Furthermore, most trials used 1% SSD cream, but its effect might be dose-related (Fuller 1994). On the other hand, higher doses could also result in higher toxicity and more adverse effects (Lansdown 2002).

Recently published literature had already suggested the lack of evidence of effectiveness for silver-containing dressings and topical agents in burns. Hussain 2006 published a Best Evidence Topic report on burns, including evidence from RCTs and CCTs. The authors concluded that there was little evidence for using silver-containing dressings to prevent wound infection, and that such products tend to delay wound healing. Furthermore, silver may have serious cytotoxic activity on various host cells (Atiyeh 2007). In minor thermal burns (less than 15% TBSA) SSD cream was found to delay healing time and increase pain when compared with other treatments (Wasiak 2006). Wasiak 2008 also evaluated different dressings for burn wounds and found evidence for a delayed healing time for SSD. Similarly, Bergin 2006 found no RCTs that evaluated the effects of silver-containing dressings for the treatment of diabetic foot ulcers, and Vermeulen 2007 found three RCTs and concluded that there was insufficient evidence of effectiveness for silver-containing dressings as a treatment for infected wounds.

The following limitations of this review should be noted

Firstly, the methodological quality of the 26 included trials was relatively low, and a large proportion of the evidence presented here is accrued from trials which demonstrate a high or uncertain risk of bias. Most of the studies had small sample sizes and were, therefore, at risk of not detecting any existing differences, and of incurring chance baseline imbalances for important prognostic factors. Only one-third of the trials reported adequate sequence generation, and even fewer reported allocation concealment. Blinding of participants and care providers was not really possible, but outcome assessors could have been blinded, or healing confirmed by blinded assessment of photographs. This was almost never achieved or reported. Similarly the drop-out rate or reasons for drop-out were not always described.

The duration of follow-up of the included studies ranged from a few days to more than three months, whilst in only five studies was follow-up continued until complete wound re-epithelialisation was achieved (Homann 2007; Mashhood 2006; Noordenbos 1999; Soroff 1994; Wyatt 1990). In some trials the length of follow-up was unclear, or too short, and almost half of the trials were supported financially by a single manufacturer. If this caused publication bias - which was shown to be present in studies on negative pressure wound therapy (Peinemann 2008) - the real effect is likely to be even less favourable.

Secondly, one strength of a systematic review is the ability to pool data from several - often small - trials to achieve greater statistical power and a more precise overall effect size estimate. In this review few data could be pooled because the trials did not compare similar interventions, and there was considerable heterogeneity in the wounds being compared. Therefore, the lack of conclusive evidence for the effects of silver-containing dressings remains.

Thirdly, some trials used repeated measurements, for example, healing rate or swabs taken (e.g. at three, six, or nine days for one endpoint). This may illustrate the eagerness of the investigators (or the sponsors) to identify any sign of a treatment difference, at the cost of an increased chance of false positive results, while the shorter intervals are not relevant to patients. Furthermore, outcome parameters were measured in different ways and on different scales. Many secondary outcomes were based on subjective concepts such as "ease of use", "comfortable to wear". These subjective findings can hardly help in clinical practice and should be measured with standardised objective measurements whenever possible. Also, some trials measured "time per dressing", or "costs per cm^2". These measures alone are meaningless and should be reported in combination with other aspects of costs.

Fourthly, the majority of studies that reported outcomes such as time to healing or time to skin grafting, incorrectly reported and analysed these outcomes as continuous - rather than time-to-event - variables. The problem with this approach is that the time to the event is only known for those people who actually experienced it (in this case healing, or grafting), and no information is obtained from those who were observed, but did not experience the event. This approach may introduce bias. Time-to-event data, such as time to wound healing, should be analysed using survival analysis in which the treatment effect is expressed as a hazard ratio.

Finally, eight trials did not attempt to define infection. Some trials defined infection only on clinical grounds and others merely on the presence of bacterial cultures. It is clearly difficult to interpret the results of studies that do not define their main outcomes. We reported the definition of infection and healing as used by the study authors and were unable to conduct any pooling due to heterogeneity.

Apart from the definition used, Sibbald 2005 stated that chronic wounds always contain bacteria and a diagnosis of infection should be based on clinical signs and not solely on bacterial cultures.

AUTHORS' CONCLUSIONS

Implications for practice

There is currently insufficient evidence that silver-containing dressings prevent wound infection or promote wound healing; the available evidence is low both in volume and quality. There is some evidence from small, poor-quality trials, that silver sulphadiazine does not reduce wound infection and slows down wound healing in people with partial-thickness burns.

Implications for research

More studies, and particularly studies with a low risk of bias, are needed to confirm any effect of silver-containing dressings in full-thickness burns and other wound groups. Future research must develop clear, valid, and reliable measures of wound infection. The use of common, quantifiable, and clinically-relevant endpoints (time to complete wound healing, number and time to wound infection, pain, adverse events, costs, and, preferably, a validated scale for patient satisfaction) should always be used. Whilst it is very difficult to blind patients and medical professionals with regard to the intervention, it is possible to blind outcome assessors, or to use computer programmes to measure wound size. Future research must adopt a survival approach for the analysis of time-to-event data, such as time to healing.

Finally, a sufficiently long follow-up period of at least six months is essential if treatment effects in chronic wounds are to be detected. Interventions under evaluation should be thoroughly, and clearly, described. For this purpose use of the revised CONSORT statement is recommended in order to report these trials adequately.

ACKNOWLEDGEMENTS

We express our gratitude to the people who refereed the protocol and review for readability, relevance, and methodological rigour: Editors David Margolis, Joan Webster and Gill Worthy, and Peer referees Charlotte Ives and Amy Zelmer and in particular thanks to Elizabeth Royle for copy editing the review.

REFERENCES

References to studies included in this review

Afilalo 1992 *{published data only}*

Afilalo M, Dankoff J, Guttman A, Lloyd J. DuoDERM hydroactive dressing versus silver sulphadiazine/Bactigras in the emergency treatment of partial skin thickness burns. *Burns* 1992;**18**(4):313-6.

Carneiro 2002 *{published data only}*

Carneiro PM, Rwanyuma LR, Mkony CA. A comparison of topical Phenytoin with Silverex in the treatment of superficial dermal burn wounds. *Central African Journal of Medicine* 2002;**48**(9/10):105-8.

Caruso 2006 *{published data only}*

Caruso DM, Foster KN, Blome-Eberwein SA, Twomey JA, Herndon DN, Luterman A, et al. Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial-thickness burns. *Journal of Burn Care and Research* 2006;**27**(3):298-309.

De Gracia 2001 *{published data only}*

De Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. *Burns* 2001;**27**(1):67-74.

Dire 1995 *{published data only}*

Dire DJ, Coppola M, Dwyer DA, Lorette JJ, Karr JL. Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED. *Academic Emergency Medicine* 1995;**2**(1):4-10.

Fang 1987 *{published data only}*

Fang CH, Nathan P, Robb EC, Alexander JW, MacMillan BG. Prospective clinical study of Hydron, a synthetic dressing, in delivery of an antimicrobial drug to second-degree burns. *Journal of Burn Care and Rehabilitation* 1987;**8**(3):206-9.

Gerding 1988 *{published data only}*

Gerding RL, Imbembo AL, Fratianne RB. Biosynthetic Skin Substitute vs. 1% Silver Sulfadiazine for Treatment of Inpatient Partial-thickness Thermal Burns. *The Journal of Trauma* 1988;**28**(8):1265-9.

Gerding 1990 *{published data only}*

Gerding RL, Emerman CL, Effron D, Lukens T, Imbembo AL, Fratianne RB. Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine. *Annals of Emergency Medicine* 1990;**19**(2):121-4.

Hansbrough 1995 *{published data only}*

Hansbrough JF, Achauer B, Dawson J, Himel H, Luterman A, Slater H, et al. Wound healing in partial-thickness burn wounds treated with collagenase ointment versus silver sulfadiazine cream. *The Journal of Burn Care and Rehabilitation* 1995;**16**(3 Pt 1):241-7.

Homann 2007 *{published data only}*

Hauser J, Rossbach O, Langer S, Vogt P, Germann G, Steinau HU, et al. Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment [Lokale Behandlung von Grad-IIa-Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin-Creme]. *Unfallchirurg 2007* 2007;**110**(11):988-94.

* Homann HH, Rosbach O, Moll W, Vogt PM, Germann G, Hopp M, et al. A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds. *Annals of Plastic Surgery* 2007;**59**(4):423-7.

Rossbach O, Vogt P, Germann G, et al. Repithel® in comparison with Flammazine® for IIa degree burns. European Wound Management Association Conference; 2005, 15-17 September; Stuttgart, Germany. 2005.

Hutchinson 1993 *{published data only}*

Allen RB, Kerstein M, Klassen H, Friedmann PS, Pryce DW, Lawrence JC, et al. Prospective study of clinical infections in wounds dressed with occlusive versus conventional dressings. 9th Annual Symposium on Advanced Wound Care and 6th Annual Medical Research Forum on Wound Repair; April 20-24; Atlanta. 1996.

* Hutchinson JJ. A prospective clinical trial of wound dressings to investigate the rate of infection under occlusion. 3rd European Conference on Advances in Wound Management; 19-22 October; Harrogate, UK. 1993.

Hutchinson JT. Influence of occlusive dressings on wound microbiology - interim results of a multi-centre clinical trial of an occlusive hydrocolloid dressing. 1st European Conference on Advances in Wound Management; 4-6 September; Cardiff, UK. 1992.

Inman 1984 *{published data only}*

Inman RJ, Snelling CF, Roberts FJ, Shaw K, Boyle JC. Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection. *Burns* 1984;**11**(1):35-40.

Innes 2001 *{published data only}*

Innes ME, Umraw N, Fish JS, Gomez M, Cartotto RC. The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study. *Burns* 2001;**27**(6):621-7.

Jacobs 2008 *{published data only}*

Jacobs AM, Tomczak R. Evaluation of Bensal HP for the treatment of diabetic foot ulcers. *Advances in Skin and Wound Care* 2008;**21**(10):461-5.

Jude 2007 *{published data only}*

Jude E. Non-ischemic diabetic foot ulcers: Effects of Aquacel Ag with hydrofiber versus alginate dressing. 2nd World Union of Wound Healing Societies Meeting, 8-13 July, Paris. 2004.

Jude E, Apelqvist J, Spraul M, Martini J. Randomized controlled study of diabetic foot ulcers dressed with hydrofiber® containing ionic silver or calcium alginate dressings. European Wound Management Association Conference,15-17 September, Stuttgart, Germany. 2005.

* Jude EB, Apelqvist J, Spraul M, Martini J, and the Silver Dressing Study Group. Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers. *Diabetic Medicine* 2007;**24**(3):280-8.

Jurczak 2007 *{published data only}*

Dugré T, Jurczak F, Offori T, et al. Randomized multi-center study comparing open surgical wound outcomes using silver or iodine dressings. European Wound Management Association Conference,15-17 September, Stuttgart, Germany. 2005.

* Jurczak F, Dugré T, Johnstone A, Offori T, Vujovic Z, Hollander D, on behalf of the AQUACEL Ag Surgical/Trauma Wound Study Group. Randomised clinical trial of Hydrofiber dressing with silver versus povidone-iodine gauze in the management of open surgical and traumatic wounds. *International Wound Journal* 2007;**4**(1):66-76.

Livingston 1990 *{published data only}*

Livingston DH, Cryer HG, Miller FB, Malangoni MA, Polk HC, Weiner LJ. A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury. *Plastic and Reconstructive Surgery* 1990;**86**(6):1059-64.

Mashhood 2006 *{published data only}*

Mashhood AA, Khan TA, Sami AN. Honey compared with 1% silver sulfadiazine cream in the treatment of superficial and partial thickness burns. *Journal of Pakistan Association of Dermatologists* 2006;**16**:14-9.

Miller 1990 *{published data only}*

Miller L, Hansbrough J, Slater H, Goldfarb IW, Kealey P, Saffle J, et al. Sildimac: a new delivery system for silver sulfadiazine in the treatment of full-thickness burn injuries. *Journal of Burn Care & Rehabilitation* 1990;**11**(1):35-41.

Muangman 2006 *{published data only}*

Muangman P, Chuntrasakul C, Silthram S, Suvanchote S, Benjathanung R, Kittidacha S, et al. Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial-thickness burn wounds. *Journal of the Medical Association of Thailand* 2006;**89**(7):953-8.

Noordenbos 1999 *{published data only}*

Noordenbos J, Doré C, Hansbrough JF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. *Journal of Burn Care and Rehabilitation* 1999;**20**(4):275-81.

Soroff 1994 *{published data only}*

Soroff HS, Sasvary DH. Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial-thickness burns: a pilot study. *Journal of Burn Care and Rehabilitation* 1994;**15**(1):13-7.

Subrahmanyam 1998 *{published data only}*

Subrahmanyam M. A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. *Burns* 1998;**24**(2):157-61.

Tredget 1998 *{published data only}*

Tredget EE, Shankowsky HA, Groeneveld A, Burrell R. A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. *Journal of Burn Care and Rehabilitation* 1998;**19**(6):531-7.

Wunderlich 1991 *{published data only}*

Wunderlich U, Orfanos CE. Treatment of venous ulcera cruris with dry wound dressings Phase overlapping use of silver impregnated activated charcoal xero-dressing. *Hautarzt* 1991;**42**(7):446-50.

Wyatt 1990 *{published data only}*

Wyatt D, McGowan DN, Najarian MP. Comparison of a hydrocolloid dressing and silver sulfadiazine cream in the outpatient management of second-degree burns. *The Journal of Trauma* 1990;**30**(7):857-65.

References to studies excluded from this review

De Boer 1981 *{published data only}*

De Boer P, Collinson PO. The use of silver sulphadiazine occlusive dressings for finger-tip injuries. *Journal of Bone and Joint Surgery* 1981;**63-B**(4):545-47.

Ganai 2002 *{published data only}*

Ganai AA, Darzi MA, Chowdri NA, Iqbal S, Zaroo MI. Prospective randomized comparative study of early surgical excision and conservative treatment for deep burns of hand. *JK Practitioner* 2002;**9**(1):24-7.

Guilbaud 1993 *{published data only}*

Guilbaud J, Honde C. Multicentre comparative clinical study of a new wound dressing: PA286 (Inerpan). *European Journal of Plastic Surgery* 1993;**16**(2):73-6.

Hadjiiski 1999 *{published data only}*

Hadjiiski OG, Lesseva MI. Comparison of four drugs for local treatment of burn wounds. *European Journal of Emergency Medicine* 1999;**6**(1):41-7.

Huang 2007 *{published data only}*

Huang Y, Li X, Liao Z, Zhang G, Liu Q, Tang J, et al. A randomized comparative trial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis. *Burns* 2007;**33**(2):161-6.

Jorgensen 2006 *{published data only}*

Ivins N, Harding KG, Price P, Jurgensen B, Lohmann M, Gottrup F, et al. Safety and efficacy in long-term use of a sustained silver-releasing foam dressing: a randomized, controlled trial on venous leg ulcers. SAWC 2006 April 30-May 3, 2006 San Antonio, Texas. 2006.

* Jorgensen B, Bech Thomsen N, Grenov B, Gottrup F. Effect of a new silver dressing on chronic venous leg ulcers with signs of critical colonisation. *International Wound Journal* 2005;**2**(1):64-73.

Lanzara 2008 *{published data only}*

Lanzara S, Tacconi G, Gianesini S, Menegatti E, Federici F, Liboni A, et al. A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers [Abstract no. 114]. *EWMA Journal* 2008;**8**(2):76.

Molnar 2004 *{published data only}*

Molnar JA, Heimbach DM, Tredgett EE, Mozingo DW. Prospective, randomized, controlled, multicenter trial applying subatmospheric pressure to acute hand burns: an interim report. 2nd World Union of Wound Healing Societies Meeting, 8-13 July, Paris. 2004.

Munster 1980 *{published data only}*

Helvig EI, Munster AM, Su CT, Oppel W. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective, randomized study. American Surgeon 1979; Vol. 45, issue 4:270-2.

Munster AM, Helvig E, Rowland S. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective evaluation. *Surgery* 1980;**88**(5):658-60.

Münter 2006 *{published data only}*

Münter KC, Beele H, Russell L, Crespi A, Grochenig E, Basse P, et al. Effect of a sustained silver-releasing dressing on ulcers with delayed healing: the CONTOP study. *Journal of Wound Care* 2006;**15**(5):199-206.

Planinsek 2007 *{published data only}*

Planinsek Rucigaj T. Comparative effects of honey based and silver/charcoal based dressings on the healing of venous leg ulcers: a randomized clinical study [Oral presentation no: 78]. 17th Conference of the European Wound Management Association; 2007, 2-4 May; Glasgow, Scotland. 2007.

Riesinger 2006 *{published data only}*

Riesinger T, Gubish ER. Clinical evaluation of the efficacy and safety of an innovative moist wound dressing (IWD), containing a nanolayer of metallic silver in patients following an extensive surgical procedure for pectus excavatum. SAWC April 30 - May 3, 2006 San Antonio, Texas. 2006.

Silver 2007 *{published data only}*

Silver GM, Robertson SW, Halerz MM, Conrad P, Supple KG, Gamelli RL. A silver-coated antimicrobial barrier dressing used postoperatively on meshed autografts: A dressing comparison study. *Journal of Burn Care and Research* 2007;**28**(5):715-9.

Stair 1986 *{published data only}*

Stair TO, D'Orta J, Altieri MF, Lippe MS. Polyurethane and silver sulfadiazene dressings in treatment of partial-thickness burns and abrasions. *American Journal of Emergency Medicine* 1986;**4**(3):214-7.

Subrahmanyam 1991 *{published data only}*

Subrahmanyam M. Topical application of honey in treatment of burns. *British Journal of Surgery* 1991;**78**(4):497-8.

Terrill 1991 *{published data only}*

Terrill PJ, Kedwards SM, Lawrence JC. The use of Gore-Tex bags for hand burns. *Burns* 1991;**17**(2):161-5.

Verdú 2004 *{published data only}*

Verdú SJ, Rueda LJ, Martinez CF, Soldevilla AJ. Effects of an activated charcoal silver dressing on chronic wounds with no clinical signs of infection. *Journal of Wound Care* 2004;**13**(10):419, 421-3.

Yue Seng 2005 *{published data only}*

Yue Seng C, Bin Sofiyan M, Bin Mohd Hashim AS. The role of nanocrystalline silver in complicated wounds in the orthopaedic ward. European Wound Management Association Conference; 2005, 15-17 September; Stuttgart, Germany. 2005.

References to studies awaiting assessment

Chen 2006 *{published data only}*

Chen J, Han CM, Lin XW, Tang ZJ, Su SJ. Effect of silver nanoparticle dressing on second degree burn wound. *Chung-Hua Wai Ko Tsa Chih* 2006;**44**(1):50-2.

Hirsch 2008 *{published data only}*

Hirsch T, Ashkar W, Schumacher O, Steinstraesser L, Ingianni G, Cedidi CC. Moist Exposed Burn Ointment (MEBO) in partial thickness burns - a randomized, comparative open mono-center study on the efficacy of dermaheal (MEBO) ointment on thermal 2nd degree burns compared to conventional therapy. *European Journal of Medical Research* 2008;**13(11)**:505-10.

Li 2006 *{published data only}*

Li XL, Huang YS, Peng YZ, Liao ZJ, Zhang GA, Liu Q, et al. Multi-center clinical study of acticoat (nanocrystalline silver dressing) for the management of residual burn wounds. *Zhonghua Shao Shang Za Zhi [Chinese Journal of Burns]* 2006;**22**(1):15-8.

Wang 2008 *{published data only}*

Wang J-W, Teng Y-J. Efficacy of ionic silver dressing and gel in local treatment of dog bite III wounds: A randomized control study. *Journal of Clinical Rehabilitative Tissue Engineering Research* 2008;**12**(14):2659-62.

References to ongoing studies

Serena 2008 *{published data only}*

Hanft J, Serena T, Snyder R. Evaluation of the clinical effectiveness of a collagen-orc antimicrobial matrix in venous leg ulcers. 16th Conference of the European Wound Management Association May 2006 Prague. 2006.

* Serena TE, Hanft JR, Snyder R. The lack of reliability of clinical examination in the diagnosis of wound infection: preliminary communication. *The International Journal of Lower Extremity Wounds* 2008;**7(1)**:32-5.

Additional references

Abedon 1998

Abedon ST. Supplemental lecture, 1998. Available from: http://www.mansfield.ohio-state.edu/~sabedon/biol2007.htm (accessed 10 January 2010).

Adeyemo 2005

Adeyemo WL, Ogunlewe MO, Ladeinde AL, Bamgbose BO. Are sterile gloves necessary in nonsurgical dental extractions?. *Journal of Oral Maxillofacial Surgery* 2005;**63**(7):936-40.

Arrowsmith 2001

Arrowsmith VA, Maunder JA, Sargent RJ, Taylor R. Removal of nail polish and finger rings to prevent surgical infection. *Cochrane Database of Systematic Reviews* 2001, Issue 4. [DOI: 10.1002/14651858.CD003325]

Atiyeh 2007

Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: review of the literature. *Burns* 2007;**33**(2):139-48.

Ballard 2002

Ballard K, McGregor F. Product Focus. Avance: silver hydropolymer dressing for critically colonised wounds. *British Journal of Nursing* 2002;**11**(3):208-11.

Balthazar 1982

Balthazar ER, Colt JD, Nichols RL. Preoperative hair removal: a random prospective study of shaving versus clipping. *Southern Medical Journal* 1982;**75**(7):799-801.

Bergin 2006

Bergin S, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. *Cochrane Database of Systematic Reviews* 2006, Issue 1. [DOI: 10.1002/14651858.CD005082.pub2]

Brett 2006

Brett DW. A discussion of silver as an antimicrobial agent: alleviating the confusion. *Ostomy Wound Manage* 2006;**52**(1):34-41.

Brooks 2001

Brooks RA, Hollinghurst D, Ribbans WJ, Severn M. Bacterial recolonization during foot surgery: a prospective randomized study of toe preparation techniques. *Foot & Ankle International* 2001;**22**(4):347-50.

Cooper 2004

Cooper R. A review of the evidence for the use of topical antimicrobials agents in wound care. World Wide Wounds. 2004:http://www.worldwidewounds.com/2004/february/Cooper/Topical–Antimicrobial-Agents.html (accessed October 19, 2008).

Cutting 2005

Cutting KF, White RJ. Criteria for identifying wound infection-revisited. *Ostomy Wound Management* 2005;**51**(1):28-34.

Dowsett 2004

Dowsett C. The use of silver-based dressings in wound care. *Nursing Standard* 2004;**19**(7):56-60.

Dunn 2004

Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. *Burns* 2004;**30**(Suppl 1):S1-9.

Edwards 2004

Edwards PS, Lipp A, Holmes A. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. *Cochrane Database of Systematic Reviews* 2004, Issue 3. [DOI: 10.1002/14651858.CD003949.pub2]

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629-34.

Fernandez 2008

Fernandez R, Griffiths R, Ussia C. Water for wound cleansing. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD003861.pub2]

Fuller 1994

Fuller FW, Parrish M, Nance FC. A review of the dosimetry of 1% silver sulfadiazine cream in burn wound treatment. *Journal of Burn Care and Rehabilitation* 1994;**15**(3):213-23.

Hartford 1981

Hartford CE. The bequests of Moncrief and Moyer: An appraisal of topical therapy of burns--1981 American burn association presidential address. *The Journal of Trauma* 1981;**21**(10):827-34.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

Higgins 2008

Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). Available from www.cochrane-handbook.org, The Cochrane Collaboration, 2008.

Hussain 2006

Hussain S, Ferguson C. Best evidence topic report. Silver sulphadiazine cream in burns. *Emergency Medicine Journal* 2006;**23**(12):929-32.

Jakobsen 1993

Jakobsen BW, Bach A, Kristensen K, Sorensen TS, Staehr H. Finger tip injuries. A comparative study of silver sulfadiazine and fucidin gauze. *Ugeskrift for Laeger* 1993;**155**(45):3654-6.

Kac 2005

Kac G, Podglajen I, Gueneret M, Vaupré S, Bissery A, Meyer G. Microbiological evaluation of two hand hygiene procedures achieved by healthcare workers during routine patient

care: a randomized study. *The Journal of Hospital Infection* 2005;**60**(1):32-9.

Karlsmark 2003

Karlsmark T, Agerslev RH, Bendz SH, Larsen JR, Roed-Petersen J, Andersen KE. Clinical performance of a new silver dressing, Contreet Foam, for chronic exuding venous leg ulcers. *Journal of Wound Care* 2003;**12**(9):351-4.

Kucan 1981

Kucan JO, Robson MC, Heggers JP, Ko F. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. *Journal of the American Geriatrics Society* 1981;**29**(5):232-5.

Lammers 1990

Lammers RL, Fourré M, Callaham ML, Boone T. Effect of povidone-iodine and saline soaking on bacterial counts in acute, traumatic, contaminated wounds. *Annals of Emergency Medicine* 1990;**19**(6):709-14.

Lansdown 2002

Lansdown AB. Silver. I: Its antibacterial properties and mechanism of action. *Journal of Wound Care* 2002;**11**(4):125-30.

Lawson 2003

Lawson C, Juliano L, Ratliff CR. Does sterile or nonsterile technique make a difference in wounds healing by secondary intention?. *Ostomy/Wound Management* 2003;**49**(4):56-8, 60.

Lefebvre 2008

Lefebvre C, Manheimer E, Glanville J. Chapter 6.4.11: Search filters. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). Available from www.cochrane-handbook.org, The Cochrane Collaboration, 2008.

Lethaby 2008

Lethaby A, Temple J, Santy J. Pin site care for preventing infections associated with external bone fixators and pins. *Cochrane Database of Systematic Reviews* 2008, Issue 4. [DOI: 10.1002/14651858.CD004551.pub2]

Mangram 1999

Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. *Infection Control and Hospital Epidemiology* 1999;**20**(4):250-78.

McLaws 2000

McLaws ML, Caelli M. Pilot testing standardized surveillance: Hospital Infection Standardised Surveillance (HISS). *American Journal of Infection Control* 2000;**28**(6):401-5.

Moore 2005

Moore ZE, Cowman S. Wound cleansing for pressure ulcers. *Cochrane Database of Systematic Reviews* 2005, Issue 4. [DOI: 10.1002/14651858.CD004983.pub2]

Moralejo 2003

Moralejo D, Jull A. Handrubbing with an aqueous alcohol solution was as effective as handscrubbing with an antiseptic soap for preventing surgical site infections. *Evidence Based Nursing* 2003;**6**(2):54-5.

Nagl 2003

Nagl M, Nguyen VA, Gottardi W, Ulmer H, Höpfl R. Tolerability and efficacy of N-chlorotaurine in comparison with chloramine T for the treatment of chronic leg ulcers with a purulent coating: a randomized phase II study. *British Journal of Dermatology* 2003;**149**(3):590-7.

O'Meara 2001

O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. *British Journal of Surgery* 2001;**88**(1):4-21.

O'Meara 2008

O'Meara S, Ovington L. Antibiotics and antiseptics for venous leg ulcers. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD003557.pub2]

Ovington 2001

Ovington LG. Nanocrystalline Silver: Where the old and familiar meets a new frontier. *Wounds: A compendium of clinical practice and research* 2001;**13**(2):4-10.

Ovington 2003

Ovington LG. Bacterial toxins and wound healing. *Ostomy/Wound Management* 2003;**49**(Suppl 7A):8-12.

Peinemann 2008

Peinemann F, McGauran N, Sauerland S, Lange S. Negative pressure wound therapy: potential publication bias caused by lack of access to unpublished study results data. *BMC Medical Research Methodology* 2008;**8**:4.

Perelman 2004

Perelman VS, Francis GJ, Rutledge T, Foote J, Martino F, Dranitsaris G. Sterile versus nonsterile gloves for repair of uncomplicated lacerations in the emergency department: a randomized controlled trial. *Annals of Emergency Medicine* 2004;**43**(3):362-70.

Rossoff 1995

Rossoff LJ, Borenstein M, Isenberg HD. Is hand washing really needed in an intensive care unit?. *Critical Care Medicine* 1995;**23**(7):1211-6.

Rotter 1997

Rotter ML. Hand washing, hand disinfection, and skin disinfection. In: RP Wenzel editor(s). Prevention and control of nosocomial infections. 3th. Baltimore: Williams & Wilkins, 1997:691–709.

Sibbald 2005

Sibbald RG, Meaume S, Kirsner RS, Münter K. Review of the clinical RCT evidence and cost-effectiveness data of a sustained-release silver foam dressing in the healing of critically colonised wounds. World Wide Wounds 2005:12.

SIGN 2008

Scottish Intercollegiate Guidelines Network (SIGN). Search filters. http://www.sign.ac.uk/methodology/filters.html#random (accessed 19 October 2008).

Stotts 1997

Stotts NA, Barbour S, Griggs K, Bouvier B, Buhlman L, Wipke-Tevis D, et al. Sterile versus clean technique in postoperative wound care of patients with open surgical wounds: a pilot study. *Journal of Wound, Ostomy, and Continence Nursing* 1997;**24**(1):10-8.

Tang 2001

Tang K, Yeh JS, Sgouros S. The Influence of hair shave on the infection rate in neurosurgery. A prospective study. *Pediatric Neurosurgery* 2001;**35**(1):13-7.

Tanner 2006

Tanner J, Woodings D, Moncaster K. Preoperative hair removal to reduce surgical site infection. *Cochrane Database of Systematic Reviews* 2006, Issue 3. [DOI: 10.1002/14651858.CD004122.pub3]

Tanner 2008

Tanner J, Swarbrook S, Stuart J. Surgical hand antisepsis to reduce surgical site infection. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD004288.pub2]

Vermeulen 2007

Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds. *Cochrane Database of Systematic Reviews* 2007, Issue 1. [DOI: 10.1002/14651858.CD005486.pub2]

Vogt 2001

Vogt PM, Hauser J, Rossbach O, Bosse B, Fleischer W, Steinau HU, et al. Polyvinyl pyrrolidone-iodine liposome hydrogel improves epithelialization by combining moisture and antisepis. A new concept in wound therapy. *Wound Repair and Regeneration* 2001;**9**(2):116-22.

Wasiak 2006

Wasiak J, Cleland H. Burns (minor thermal). *BMJ Clinical Evidence* 2007;**12**(1903):1-14.

Wasiak 2008

Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. *Cochrane Database of Systematic Reviews* 2008, Issue 4. [DOI: 10.1002/14651858.CD002106.pub3]

Wilson 1986

Wilson GR, Fowler C, Ledger J, Thorley M. Evaluation of a new antiseptic dressing in minor burns. *Burns Incl Therm Injury* 1986;**12**(7):518-20.

Wilson 2004

Wilson AP, Gibbons C, Reeves BC, Hodgson B, Liu M, Plummer D, Krukowski ZH, Bruce J, Wilson J, Pearson A. Surgical wound infection as a performance indicator: agreement of common definitions of wound infection in 4773 patients. *BMJ* 2004;**329**(7468):720.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Afilalo 1992

Methods	Computer-generated random numbers table
Participants	n = 48 Patients in Emergency Department with partial-thickness burns, <15% TBSA Duration of wound in both groups: < 48 hours Unit of allocation: patient Period of follow-up: not reported
Interventions	Group 1: SSD cream (1%) with chlorhexidine-impregnated gauze (Bactigras®) (n = 15) Group 2: hydrocolloid dressing (Duoderm®) (n = 15)
Outcomes	Infection rate; wound healing rate; pain; patient satisfaction
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Canada Definition of infection: not reported Concurrent illness: none

Afilalo 1992 *(Continued)*

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Computer-generated random numbers table
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Participants, caregivers and outcome assessors not blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	High risk	18 dropouts were described: follow-up 62% A reason for drop out was occurrence of infection (n = 3)
Incomplete outcome data addressed? ITT analysis	High risk	ITT not reported, but patients were excluded from analysis when they would not comply with the protocol
Financial support for trial or trialists?	High risk	Supported, in part, by a grant from Convatec Division of Bristol-Meyers
Groups similar at baseline?	Low risk	Authors stated no significant differences with respect to location, size and causative agent
Co interventions avoided or similar?	Low risk	Same cleaning of the wound and instructions given

Carneiro 2002

Methods	Randomised
Participants	n = 64 Patients with 2nd degree burns, < 30% TBSA Duration of wound: not reported for either group Unit of allocation: patient Period of follow-up: until discharge
Interventions	Group 1: SSD/chlorhexidine (Silverex) (n = 32) Group 2: Diphenyldantoin (phenytoin) (n = 32)
Outcomes	Infection rate; wound healing rate; pain; length of hospital stay
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Tanzania Definition of infection: cultures Concurrent illness: none

Risk of bias

Bias	Authors' judgement	Support for judgement

Carneiro 2002 *(Continued)*

Adequate sequence generation?	Unclear risk	Reported as "Randomised, controlled, prospective study"
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	No dropouts were reported: follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	Not stated, but evident from study assessment
Financial support for trial or trialists?	High risk	Support for the trial from Dreyfus Health Foundation, New York
Groups similar at baseline?	Low risk	Authors stated no significant differences with respect to age, sex and extent of burn injury. Also no significant difference in positive bacterial cultures obtained on admission
Co interventions avoided or similar?	Low risk	Same cleaning of the wound, same wound assessment procedure.

Caruso 2006

Methods	Stratified randomisation schedule
Participants	n = 84 Patients with superficial, mid-dermal or mixed partial-thickness burns of 5-40% TBSA Duration of wound in both groups: < 36 hours Unit of allocation: patient Period of follow-up: 3 weeks
Interventions	Group 1: SSD cream (n = 40) Group 2: hydrofibre dressing containing ionic silver (Aquacel® Ag) (n = 42)
Outcomes	Infection rate; wound healing rate; adverse effects; use of systemic antibiotics; pain; costs
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: USA Definition of infection: not reported Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Stratified randomisation schedule

Caruso 2006 *(Continued)*

Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Authors stated that the study treatment was not blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	2 dropouts described: follow-up 98%
Incomplete outcome data addressed? ITT analysis	High risk	2 participants did not receive study treatment and, therefore, were not analysed
Financial support for trial or trialists?	High risk	The trial was supported by a grant from Convatec, a Bristol-Myers Squibb company. Convatec supervised the design, data-analysis and the development of the manuscript of this study
Groups similar at baseline?	Low risk	Authors stated baseline characteristics were comparable
Co interventions avoided or similar?	Unclear risk	Not reported

De Gracia 2001

Methods	Patients assigned consecutively according to a pre-established randomised sequence
Participants	n = 60 Patients with moderate and severe burns, >15% TBSA Duration of wound in both groups: < 24 hours Unit of allocation: patient Period of follow-up: not reported
Interventions	Group 1: SSD cream (Flamazine®) (n = 30) Group 2 SSD/cerium-nitrate (Flammacerium®) (n = 30)
Outcomes	Infection rate; wound healing rate; adverse effects; use of systemic antibiotics; length of hospital stay
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: yes
Notes	Country: Philippines Definition of infection: cultures and clinical criteria Concurrent illness: majority none

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Unclear risk	Patients were assigned consecutively according to a pre-established randomised sequence
Allocation concealment?	Unclear risk	Not reported

De Gracia 2001 *(Continued)*

Blinding? All outcomes	Unclear risk	Stated that double-blinding was not possible, but not explicitly reported for the outcome assessor
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	11 dropouts were described, but only 1 patient was not included in the analysis
Incomplete outcome data addressed? ITT analysis	High risk	One participant was not analysed due to poor compliance
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	No significant difference with respect to age. The extent of burn injury differed, but was compensated with multiple linear regression analysis
Co interventions avoided or similar?	Low risk	Cleansing of wounds and other treatments stated

Dire 1995

Methods	Randomised, opaque numbered vials
Participants	n = 465 Patients with minor, uncomplicated soft-tissue wounds necessitating suturing Duration of wound in both groups: < 12 hours Unit of allocation: patient Period of follow-up: not reported
Interventions	Group 1: SSD cream (n = 99) Group 2: BAC (n = 109) Group 3: neomycin sulfate (n = 110) Group 4: petrolatum (n = 108)
Outcomes	Infection rate
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Texas Definition of infection: clinical criteria Concurrent illness: none

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomised, opaque numbered vials
Allocation concealment?	Unclear risk	Study agent in randomised opaque vials labelled with identification numbers, but not clear whether the person responsible for determining eligibility of participants had influence on the assignment sequence

Dire 1995 *(Continued)*

Blinding? All outcomes	Low risk	Reported as double-blinded: likely that the outcome assessor was blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	39 dropouts were described: follow-up 92%
Incomplete outcome data addressed? ITT analysis	High risk	1 participant received the wrong study treatment and was excluded from analysis
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	No significant differences with respect to age, or wounds' depth and location
Co interventions avoided or similar?	Low risk	Same wound treatment except for study agent

Fang 1987

Methods	Selected at random
Participants	n = 27 (54 wound sites) Patients with similar size and injury-matched areas of 2nd degree burns Duration of wound: not reported in either group Unit of allocation: wounds Period of follow-up: not reported
Interventions	Group 1: SSD cream (1%) (n = 27) Group 2: synthetic dressing containing silver (Hydron AgSD (1-3%)) (n = 27)
Outcomes	Infection rate; wound healing rate
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: China Definition of infection: cultures Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Selected at random
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported for participants and caregivers Outcome assessors not blinded

Fang 1987 *(Continued)*

Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Unclear risk	Not reported
Incomplete outcome data addressed? ITT analysis	Unclear risk	Not reported
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	Author reported the wounds as injury and size matched.
Co interventions avoided or similar?	Low risk	Participants acted as their own control

Gerding 1988

Methods	Computer-generated codes within sealed, numbered envelopes that were opened sequentially
Participants	n = 47 (50 wounds) Inpatients with acute partial-thickness burns Duration of wound in both groups: < 6 hours Unit of allocation: wounds Period of follow-up: not reported
Interventions	Group 1: SSD cream (1%) (n = 23) Group 2: biosynthetic dressing (Biobrane®) (n = 27)
Outcomes	Infection rate; wound healing rate; pain; costs
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: USA Definition of infection: cultures and clinical criteria Concurrent illness: not reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Low risk	Computer-generated codes within sealed, numbered envelopes that were opened sequentially
Allocation concealment?	Low risk	Sequentially-opened sealed, numbered envelopes
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed?	Low risk	4 dropouts described: follow-up 91%

Gerding 1988 *(Continued)*

Drop out rate described and acceptable (> 80%)		
Incomplete outcome data addressed? ITT analysis	High risk	1 participant excluded from analysis due to protocol violation
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	Author stated no differences for sex, race and burn agent
Co interventions avoided or similar?	Low risk	Same wound treatment except for study agent. 7 participants acted as their own control

Gerding 1990

Methods	Computer-generated codes within sealed, numbered envelopes that were opened sequentially
Participants	n = 64 (analysed 56 wounds) Outpatients with acute partial-thickness thermal burns, < 10% TBSA Duration of wound in both groups: < 24 hours Unit of allocation: wounds Period of follow-up: not reported
Interventions	Group 1: SSD cream (1%) (n = 26) Group 2: biosynthetic dressing (Biobrane®) (n = 30)
Outcomes	Infection rate; wound healing rate; pain; costs
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: not reported
Notes	Country: USA Definition of infection: clinical criteria, but not described in detail Concurrent illness: not reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Low risk	Computer-generated codes within sealed, numbered envelopes that were opened sequentially
Allocation concealment?	Low risk	Sequentially-opened sealed, numbered envelopes
Blinding? All outcomes	High risk	Participants, caregivers and outcome assessors not blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	12 dropouts described: follow-up 81%

Gerding 1990 *(Continued)*

Incomplete outcome data addressed? ITT analysis	High risk	5 participants excluded from analysis due to protocol violations
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	Author stated no differences for sex, race and TBSA burned
Co interventions avoided or similar?	Low risk	Same cleaning of the wound and follow-up procedure

Hansbrough 1995

Methods	Randomly assigned
Participants	n = 79 (158 wounds) Patients with 2 similar partial-thickness burns of 1-25% TBSA Duration of wound in both groups: < 4 days Unit of allocation: wounds Period of follow-up: not reported
Interventions	Group 1: SSD cream (1%) (Silvadene) (n = 79) Group 2: collagenase ointment applied with polymyxin B sulfate/bacitracin powder (Santyl®) (n = 79)
Outcomes	Infection rate; wound healing rate; pain
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: USA Definition of infection: not reported Concurrent illness: not reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Unclear risk	Randomly assigned
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Although a designated observer evaluated time to clean wound bed, not reported whether observer was blinded regarding treatment
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	High risk	34 participants discontinued early and described. Follow-up 56%
Incomplete outcome data addressed? ITT analysis	Low risk	Participants with incomplete data assigned censored values for missing data points

Hansbrough 1995 *(Continued)*

Financial support for trial or trialists?	High risk	Study sponsored by Knoll Pharmaceutical Company, Whyppany, NJ
Groups similar at baseline?	Low risk	No significant differences for wound size and location
Co interventions avoided or similar?	Low risk	Participants acted as their own control

Homann 2007

Methods	Computer-generated randomisation list
Participants	n = 47 Patients with 2 comparable partial-thickness burns (degree IIa) without wound infection, < 50% TBSA Duration of wound in both groups: < 72 hours Unit of allocation: wounds Period of follow-up: until healing
Interventions	Group 1: SSD cream (n = 43) Group 2: liposome hydrogel with PVP-I (n = 43)
Outcomes	Infection rate; wound healing rate; adverse effects; pain
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Germany Definition of infection: clinical criteria Concurrent illness: not sufficiently reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Low risk	Computer-generated randomisation list using the program Rancode
Allocation concealment?	Unclear risk	Not sufficiently reported
Blinding? All outcomes	Low risk	Participants and caregivers not blinded; outcome assessors blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	4 participants excluded due to protocol violations for inclusion criteria, and 4 participants did not complete the study: follow-up 91%
Incomplete outcome data addressed? ITT analysis	High risk	4 participants excluded due to protocol violations
Financial support for trial or trialists?	High risk	The study was sponsored by Mundipharma GmbH

Homann 2007 *(Continued)*

Groups similar at baseline?	Low risk	No significant difference for wound size
Co interventions avoided or similar?	Low risk	Participants acted as their own control

Hutchinson 1993

Methods	Prospective, controlled, randomised investigation
Participants	n = 292 Patients with venous leg ulcers, partial-thickness burns or partial-thickness donor sites. Duration of wound in both groups: not reported for burns or donor sites. Duration of wound for leg ulcers: Group 1: 318 weeks; Group 2: 102 weeks; Group 3: 162 weeks. Unit of allocation: patient. Period of follow-up: for burns and donor sites 3 weeks; for leg ulcers 10 weeks
Interventions	Group 1: SSD cream/hydrocolloid (n = 58) Group 2: hydrocolloid (n = 108) Group 3: non-occlusive paraffin impregnated gauze (n = 126)
Outcomes	Infection rate
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: USA, United Kingdom, Netherlands Definition of infection: clinical criteria Concurrent illness: not reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Unclear risk	Prospective, controlled, randomised investigation
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	High risk	70 dropouts, reasons not described: follow-up 76%
Incomplete outcome data addressed? ITT analysis	Unclear risk	Not reported
Financial support for trial or trialists?	High risk	Author works for ConvaTec Ltd

Hutchinson 1993 *(Continued)*

Groups similar at baseline?	Low risk	Groups statistically homogeneous
Co interventions avoided or similar?	Unclear risk	Not reported

Inman 1984

Methods	Randomly assigned
Participants	n = 121 Patients with fresh full-thickness burns Duration of wound in both groups: < 24 hours Unit of allocation: patient Period of follow-up: not reported
Interventions	Group 1: SSD cream (Flamazine®) (n = 54) Group 2: SSD/chlorhexidine digluconate cream (0.2%) (Silvazine®) (n = 67)
Outcomes	Infection rate; use of systemic antibiotics; pain
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Canada Definition of infection: clinical criteria accompanied with cultures with > 10^5 organisms per gram of tissue Concurrent illness: not sufficiently reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Unclear risk	Randomly assigned
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Unclear risk	Reasons for drop out described, but number of excluded participants not reported. Unclear if follow-up was > 80%
Incomplete outcome data addressed? ITT analysis	High risk	Not all participants included in the analysis according to randomisation group to which allocated. Patients excluded from analysis if they did not survive for 7 days, if all eschar excised before day 7, and if they were discharged before day 7
Financial support for trial or trialists?	High risk	Funding support for microbiological studies and statistical analysis by British Columbia Professional Firefighters Association, and Smith and Nephew

Inman 1984 *(Continued)*

Groups similar at baseline?	High risk	Groups comparable, except that scald burns more frequent in SSD group. No adjustment made in the analysis
Co interventions avoided or similar?	Low risk	Same wound cleaning and same procedure when cultures were taken

Innes 2001

Methods	Randomisation table assigned dressings to site A or site B
Participants	n = 17 (32 wound sites) Patients with burns who required split-thickness skin graft Duration of wound in both groups: not reported Unit of allocation: wounds Period of follow-up: > 3 months
Interventions	Group 1: nanocrystalline silver-coated dressing (Acticoat®) (n = 16) Group 2: hydrophilic polyurethane dressing (Allevyn®) (n = 16)
Outcomes	Infection rate; wound healing rate; costs
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Canada Definition of infection: cultures and clinical criteria Concurrent illness: not sufficiently reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomisation table assigned dressings to either site A or B
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Not reported for participants; caregivers not blinded. Although authors stated that 4 independent observers viewed standard images of wounds for re-epitheliailisation and that scar was rated by a blinded observer, they stated that the daily wound observer was an experienced burn surgeon. It is likely that he was not blinded to the treatment
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	2 dropouts described: follow-up 88%
Incomplete outcome data addressed? ITT analysis	Low risk	Not stated, but evident from study assessment
Financial support for trial or trialists?	Unclear risk	Not reported

Innes 2001 *(Continued)*

Groups similar at baseline?	Low risk	No differences in wound size
Co interventions avoided or similar?	Low risk	Participants acted as their own controls

Jacobs 2008

Methods	Randomly assigned
Participants	n = 40 Diabetic patients with Wagner grade 1 or 2 ulcers Duration of wound in both groups: not reported Unit of allocation: patients Period of follow-up: 6 weeks
Interventions	Group 1: SSD cream (n = 20) Group 2: benzoic acid-6%, salicylic acid-3% and *Quercus rubra* extract-3% (Bensal HP) (n = 20)
Outcomes	Infection rate; wound healing rate
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: Canada Definition of infection: cultures and clinical criteria Concurrent illness: all patients had diabetes, patients with peripheral vascular disease were excluded. Additional co-morbid conditions were not evaluated

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Low risk	Drawing marbles of different colours out of a sock; marbles were not replaced (information retrieved from author)
Allocation concealment?	High risk	Participants blindly drew a marble out of a sock. This technique has a high risk of subversion since there is no audit trail
Blinding? All outcomes	Unclear risk	Not sufficiently reported. The authors stated that the study was blinded, but did not report who was blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	Stated, that there were no dropouts; follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	Not stated, but evident from study assessment
Financial support for trial or trialists?	Unclear risk	Not reported

Jacobs 2008 *(Continued)*

Groups similar at baseline?	Low risk	Groups comparable for wound size, and authors stated that there were no differences between the two groups
Co interventions avoided or similar?	Low risk	All patients treated with off-loading, debridement, instructions for application, wound coverage

Jude 2007

Methods	Randomly assigned to instructions in a sealed envelope
Participants	n = 134 Patients with diabetic foot ulcers of Wagner grade 1 or 2 of non-ischaemic aetiology with area ≥1 cm^2 Duration of wound in both groups: not reported Unit of allocation: patient Period of follow-up: 8 weeks
Interventions	Group 1: hydrofibre dressing containing ionic silver (Aquacel® Ag) (n = 67) Group 2: calcium alginate dressing (Algosteril®) (n = 67)
Outcomes	Infection rate; wound healing rate; adverse effects
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: United Kingdom, Germany, Sweden, France Definition of infection: clinical criteria Concurrent illness: DM, types 1 and 2

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Low risk	Randomly assigned to instructions in a sealed envelope
Allocation concealment?	Unclear risk	Instructions in a sealed envelope, but not clear if the envelopes were sequentially numbered and opaque
Blinding? All outcomes	High risk	Participants, caregivers and outcome assessors not blinded: open label
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	21 participants discontinued the study, but were included in the ITT analysis
Incomplete outcome data addressed? ITT analysis	Low risk	Stated as undertaken
Financial support for trial or trialists?	High risk	Study supported by clinical grant from ConvaTec, a Bristol-Myers Squibb Company, Princeton, NJ, USA
Groups similar at baseline?	Unclear risk	It seemed that at baseline there were larger ulcers in the control group and more frequent use of antibiotics in the hydrofibre-silver group

Jude 2007 *(Continued)*

Co interventions avoided or similar?	Low risk	Same wound cleansing and treatment, except for study agent

Jurczak 2007

Methods	Computer-generated randomisation scheme with sealed envelopes opened sequentially
Participants	n = 67 Patients with open surgical wounds or open traumatic wounds left to heal by secondary intent and requiring an antimicrobial dressing Duration of wound in both groups: < 12 hours Unit of allocation: patient Period of follow-up: 2 weeks
Interventions	Group 1: Hydrofibre dressing containing ionic silver (Aquacel® Ag) (n = 35) Group 2: povidone iodine gauze (n = 32)
Outcomes	Infection rate; wound healing rate; adverse effects; pain
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: Great Britain, Germany, France Definition of infection: clinical criteria Concurrent illness: not sufficiently reported

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Adequate sequence generation?	Low risk	Computer-generated randomisation scheme with sealed envelopes opened sequentially
Allocation concealment?	Low risk	Sequentially-opened, sealed, numbered envelopes
Blinding? All outcomes	High risk	Participants, caregivers and outcome assessors not blinded: open label study
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	5 dropouts described
Incomplete outcome data addressed? ITT analysis	Low risk	Dropouts included in the ITT analysis for primary endpoints
Financial support for trial or trialists?	High risk	Study supported by grant from Convatec, a Bristol-Myers Squibb Company. Convatec monitored study design, study conduct, and data collection, and supervised data analysis and preparation of the manuscript
Groups similar at baseline?	Low risk	Only mean ulcer area was larger in the povidone iodine gauze group due to an outlier (976 mm^2 vs 1463 mm^2), but median ulcer area was comparable (both 600 mm^2)

Jurczak 2007 *(Continued)*

Co interventions avoided or similar?	Low risk

Livingston 1990

Methods	Randomisation by labelling cards, shuffling and drawing in blinded fashion; because of resulting imbalance in group size, last 7 consecutive patients all placed in silver nitrate group
Participants	n = 52 Patients with thermal injury who required skin grafting Duration of wound in both groups: Group 1: mean 3-4 days to first graft; Group 2: mean 4 days; Group 3: 4-9 days Unit of allocation: patient Period of follow-up: not reported
Interventions	Group 1: silver nitrate 0.5% (n = 19) Group 2: Ringer's lactate (n = 15) Group 3: neomycin (1 g/L) + bacitracin (50,000 Units/L) (n = 18)
Outcomes	Infection rate; length of hospital stay
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: USA Definition of infection: > 10^5 organisms per gram of tissue Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Randomisation by labelling cards, shuffling and drawing in blinded fashion
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	No dropouts reported: follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	Evident from study assessment
Financial support for trial or trialists?	Unclear risk	Not reported

Livingston 1990 *(Continued)*

Groups similar at baseline?	Unclear risk	Average age and percentage TBSA similar, however, operative procedures and hospital stay not similar
Co interventions avoided or similar?	Low risk	Same nutritional support and antibiotic prophylaxis

Mashhood 2006

Methods	Randomly divided into two groups
Participants	n = 50 Patients with superficial and partial-thickness burns, < 15% TBSA Duration of wound in both groups: not reported Unit of allocation: patient Period of follow-up: 6 months
Interventions	Group 1: SSD cream (n = 25) Group 2: honey (pure, unprocessed, and undiluted) (n = 25)
Outcomes	Wound healing rate; pain; costs
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: Pakistan Definition of infection: cultures and clinical criteria Concurrent illness: none

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomly divided into two groups
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	No dropouts reported: follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	Evident from study assessment
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Unclear risk	Not reported

Mashhood 2006 *(Continued)*

Co interventions avoided or similar?	Low risk	General management in wound care was the same

Miller 1990

Methods	Computer-generated randomisation schedule
Participants	n = 59 Patients with full-thickness burns, < 40% TBSA Duration of wound in both groups: < 48 hours Unit of allocation: wounds Period of follow-up: 2 weeks
Interventions	Group 1: SSD cream (Silvadene) (n = 51) Group 2: Polyethylene glycol 400, poly-2-hydroxyethyl methacrylate, and dimethyl sulfoxide: Dimac-containing SSD (Sildimac®) (n = 51)
Outcomes	Infection rate; adverse effects
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: yes
Notes	Country: USA Definition of infection: > 10^5 organisms per gram of tissue Concurrent illness: none

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Computer-generated randomisation schedule
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported for outcome assessors. Blinding was not possible for participants
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	8 dropouts described; follow-up 86%
Incomplete outcome data addressed? ITT analysis	Unclear risk	ITT used for adverse effects, but 8 participants not analysed for infection rate
Financial support for trial or trialists?	High risk	Partly supported by grant from Marion Laboratories, Inc
Groups similar at baseline?	Low risk	Participants with two comparable wound sites. No significant difference before treatment in number of positive biopsies
Co interventions avoided or similar?	Low risk	Participants acted as their own controls

Muangman 2006

Methods	Randomised into two groups
Participants	n = 50 Patients with partial-thickness burns, < 25% TBSA Duration of wound in both groups: not reported Unit of allocation: patient Period of follow-up: not reported
Interventions	Group 1: SSD cream (n = 25) Group 2: nanocrystalline silver-coated dressing (Acticoat®) (n = 25)
Outcomes	Infection rate; pain; length of hospital stay
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: Thailand Definition of infection: swabs and clinical criteria Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomised into two groups
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Not explicitly stated, but materials different, so participants and caregivers not blinded. Not reported for outcome assessor
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	No dropouts reported: follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	All participants included in analysis, not likely that ITT was violated
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	No differences in baseline characteristics
Co interventions avoided or similar?	Unclear risk	Not reported

Noordenbos 1999

Methods	Randomised, chosen wound sites

Noordenbos 1999 *(Continued)*

Participants	n = 14 Patients with 2 comparable-sized, moderate to deep, partial-thickness burns of 2-30% TBSA Duration of wound in both groups: < 24 hours Unit of allocation: wounds Period of follow-up: 12 months
Interventions	Group 1: SSD cream (n = 14) Group 2: biosynthetic dressing with skin substitute (Transcyte on Biobrane mesh) (n = 14)
Outcomes	Infection rate; wound healing rate
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: not reported
Notes	Country: USA Definition of infection: not reported Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomised, chosen wound sites
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Non-blinded study: participants, caregivers and outcome assessors not blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	No dropouts reported: follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	Evident from study assessment
Financial support for trial or trialists?	Low risk	Non-sponsored, investigator-initiated investigational device exemption
Groups similar at baseline?	Low risk	Participants with two comparable-sized wound sites
Co interventions avoided or similar?	Low risk	Participants acted as their own controls

Soroff 1994

Methods	Randomisation schedule
Participants	n = 15 Patients with partial-thickness burns, < 25% TBSA Duration of wound in both groups: 1-10 days Unit of allocation: wounds

Soroff 1994 *(Continued)*

	Period of follow-up: till healing
Interventions	Group 1: SSD cream (n = 15) Group 2: collagenase ointment applied with polymyxin B sulfate/Bacitracin spray (n = 15)
Outcomes	Wound healing rate
Miscellaneous quality issues	Medical Ethics Committee: approved the trial Informed consent: yes
Notes	Country: USA Definition of infection: not reported Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomisation schedule
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Not explicitly stated, but materials were different, so participants and caregivers not blinded. Not reported for outcome assessor
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	2 dropouts described: follow-up 87%
Incomplete outcome data addressed? ITT analysis	High risk	1 cross-over not treated as randomised and, therefore, there was no ITT analysis
Financial support for trial or trialists?	High risk	Supported by Knoll Pharmaceutical Company
Groups similar at baseline?	Unclear risk	Although the author stated that groups were not statistically different, the mean burn size was larger in the collagenase group (182.7 cm^2 vs 163.7 cm^2)
Co interventions avoided or similar?	Low risk	Participants acted as their own controls

Subrahmanyam 1998

Methods	Randomly allocated to two groups
Participants	n = 50 Patients with superficial thermal burns, < 40% TBSA Duration of wound in both groups: < 6 hours Unit of allocation: patient Period of follow-up: > 3 weeks
Interventions	Group 1: SSD cream (n = 25)

Subrahmanyam 1998 *(Continued)*

	Group 2: honey (pure, unprocessed, undiluted from the hive) (n = 25)
Outcomes	Infection rate; wound healing rate
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: India Definition of infection: clinical criteria Concurrent illness: not reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomly allocated to two groups
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Not explicitly stated, but materials were different, so participants and caregivers not blinded. Not reported for outcome assessor
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	No dropouts reported: follow-up 100%
Incomplete outcome data addressed? ITT analysis	Low risk	Evident from study assessment
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	No differences in baseline characteristics
Co interventions avoided or similar?	Low risk	Same wound assessment and same procedure when biopsies were taken

Tredget 1998

Methods	Computer-generated randomisation schedule
Participants	n = 30 (60 wounds) Patients with deep partial- and full-thickness burns Duration of wound in both groups: < 72 hours Unit of allocation: wounds Period of follow-up: mean 4 days (until first operative procedure)
Interventions	Group 1: nanocrystalline silver-coated dressing (Acticoat®) (n = 30) Group 2: fine-mesh gauze moistened with a 0.5% solution of silver nitrate (n = 30)
Outcomes	Infection rate; wound healing rate; pain

Tredget 1998 *(Continued)*

Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: yes
Notes	Country: Canada Definition of infection: > 10^5 organisms per gram of tissue Concurrent illness: none

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Computer-generated randomisation schedule
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Unclear risk	Not reported
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	1 dropout described: follow-up 97%
Incomplete outcome data addressed? ITT analysis	Low risk	Evident from study assessment
Financial support for trial or trialists?	High risk	Supported by funding from the Westaim Corporation, Fort Saskatchewan, Alberta, Canada
Groups similar at baseline?	Low risk	Two comparable wounds
Co interventions avoided or similar?	Low risk	Participants acted as their own controls

Wunderlich 1991

Methods	Randomised
Participants	n = 40 Patients with venous leg ulcers Duration of wound in both groups: Group 1: 7.6 years; Group 2: 7.9 years Unit of allocation: patient Period of follow-up: 6 weeks
Interventions	Group 1: activated charcoal xerodressing silver-impregnated (SIAX) (Actisorb plus) (n = 19) Group 2: conventional phase-adapted therapy using diverse topical modalities (n = 19)
Outcomes	Infection rate; wound healing rate
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: not reported
Notes	Country: Germany

Wunderlich 1991 *(Continued)*

	Definition of infection: swabs Concurrent illness: DM excluded, other ulcers excluded

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomised
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	High risk	Open RCT: participants, caregivers and outcome assessors not blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	2 dropouts described: follow-up 95%
Incomplete outcome data addressed? ITT analysis	Low risk	Evident from study assessment
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	Baseline characteristics similar
Co interventions avoided or similar?	Low risk	Same wound care, except for study agent

Wyatt 1990

Methods	Randomly assigned
Participants	n = 50 Patients with minor second degree burns Duration of wound in both groups: < 48 hours Unit of allocation: patient Period of follow-up: until healing
Interventions	Group 1: SSD cream (n = 20) Group 2: hydrocolloid (Duoderm® Hydroactive) (n = 22)
Outcomes	Infection rate; wound healing rate; pain
Miscellaneous quality issues	Medical Ethics Committee: not reported Informed consent: yes
Notes	Country: USA Definition of infection: clinical criteria, but not described in detail Concurrent illness: none

Risk of bias

Wyatt 1990 *(Continued)*

Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomly assigned
Allocation concealment?	Unclear risk	Not reported
Blinding? All outcomes	Low risk	Participants, caregivers not blinded Outcome assessor blinded
Incomplete outcome data addressed? Drop out rate described and acceptable (> 80%)	Low risk	8 dropouts described: follow-up 84%
Incomplete outcome data addressed? ITT analysis	High risk	Four participants were wrongfully randomised and therefore excluded from analysis. Four other participants were lost to follow-up and not analysed
Financial support for trial or trialists?	Unclear risk	Not reported
Groups similar at baseline?	Low risk	No significant differences for baseline characteristics
Co interventions avoided or similar?	Low risk	Same wound assessment and follow-up

Abbreviations
< = less than
> = more than
≥ = more than or equal to
BAC = bacitracin zinc ointment
DM = diabetes mellitus
ITT = intention-to-treat analysis
PVP-I = polyvinyl-pyrrolidone iodine
SSD = silver sulphadiazine
TBSA = total surface body area
vs = versus

Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
De Boer 1981	Not an RCT
Ganai 2002	No comparison of dressings
Guilbaud 1993	Almost no silver used, and no separate figures reported on the effect of silver
Hadjiiski 1999	Not an RCT
Huang 2007	Wounds already infected at inclusion
Jorgensen 2006	Wounds already infected at inclusion

Study	Reason for exclusion
Lanzara 2008	Only abstract available; no response to attempts to contact investigator
Molnar 2004	Only abstract available; no response to attempts to contact investigator
Munster 1980	Not an RCT
Münter 2006	Wounds already infected at inclusion
Planinsek 2007	Only abstract available; no response to attempts to contact investigator
Riesinger 2006	Only abstract available; not able to retrieve contact information
Silver 2007	Not an RCT
Stair 1986	Cross-over study
Subrahmanyam 1991	The aim of the study was not prevention of infection
Terrill 1991	Compared the bacteriological properties and clinical performance of polythene and polytetrafluoroethylene fabric bags, both containing SSD. The silver-containing dressings were not compared.
Verdú 2004	Not an RCT
Yue Seng 2005	Only abstract available; no response to attempts to contact investigator

Characteristics of studies awaiting assessment *[ordered by study ID]*

Chen 2006

Methods	Randomly divided
Participants	Patients with superficial and deep burns (n = 191)
Interventions	Group 1: SSD cream Group 2: silver nanoparticle dressing Group 3: Vaseline gauze
Outcomes	Infection rate; wound healing rate
Notes	Article in Chinese

Hirsch 2008

Methods	Single-centred randomised clinical trial
Participants	Patients with second degree burns (n = 40)
Interventions	Group 1: SSD cream (Flamazine) Group 2: moist exposed burn ointment (MEBO)

Hirsch 2008 *(Continued)*

Outcomes	Infection rate; wound healing rate; pain
Notes	

Li 2006

Methods	Multi-centred randomised clinical trial
Participants	Patients with residual burns (n = 98; 166 wounds)
Interventions	Group 1: SSD cream Group 2: nanocrystalline silver dressing (Acticoat)
Outcomes	Wound healing time
Notes	Article in Chinese

Wang 2008

Methods	Randomised control study
Participants	Patients with wounds from dog bites (n = 40)
Interventions	Group 1: ionic silver dressing (Aquacel) Group 2: Duoderm Hydroactive gel
Outcomes	Wound healing
Notes	Article in Chinese

Characteristics of ongoing studies *[ordered by study ID]*

Serena 2008

Trial name or title	The lack of reliability of clinical examination in the diagnosis of wound infection: preliminary communication
Methods	Multicentred randomised clinical trial
Participants	Patients with chronic venous leg ulcers (n = 49)
Interventions	Collagen-ORC antimicrobial matrix compared with moist wound dressings
Outcomes	Reduction in wound area, number of wounds healed in 12 weeks, infection, healing rate, pain, quality of life, ease of use
Starting date	August 2004 to October 2005
Contact information	

Serena 2008 *(Continued)*

Notes	Conference proceedings and preliminary results

DATA AND ANALYSES

Comparison 1. Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	2	106	Risk Difference (M-H, Fixed, 95% CI)	-0.00 [-0.12, 0.12]
2 Mean pain scores	2	106	Mean Difference (IV, Fixed, 95% CI)	1.41 [0.99, 1.83]
3 Costs based on hospital charges (US dollars)	1	56	Mean Difference (IV, Fixed, 95% CI)	70.0 [15.54, 124.46]

Analysis 1.1. Comparison 1 Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Biobrane n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Gerding 1988	4/23	4/27		47.14%	0.03[-0.18,0.23]
Gerding 1990	2/26	3/30		52.86%	-0.02[-0.17,0.13]
Total (95% CI)	**49**	**57**		**100%**	**-0[-0.12,0.12]**
Total events: 6 (SSD), 7 (Biobrane)					
Heterogeneity: Tau^2=0; Chi^2=0.15, df=1(P=0.7); I^2=0%					
Test for overall effect: Z=0(P=1)					



Analysis 1.2. Comparison 1 Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®), Outcome 2 Mean pain scores.

Study or subgroup	SSD N	SSD Mean(SD)	Biobrane N	Biobrane Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
Gerding 1988	23	3.8 (0.8)	27	2.4 (0.7)		98.05%	1.4[0.98,1.82]
Gerding 1990	26	3.6 (6.6)	30	1.6 (4.4)		1.95%	2[-0.99,4.99]
Total ***	**49**		**57**			**100%**	**1.41[0.99,1.83]**
Heterogeneity: Tau^2=0; Chi^2=0.15, df=1(P=0.7); I^2=0%							
Test for overall effect: Z=6.62(P<0.0001)							

Analysis 1.3. Comparison 1 Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®), Outcome 3 Costs based on hospital charges (US dollars).



Comparison 2. SSD cream (1%) vs biosynthetic dressing with skin substitute (Transcyte® on Biobrane® mesh)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	28	Risk Difference (M-H, Fixed, 95% CI)	0.43 [0.16, 0.70]

Analysis 2.1. Comparison 2 SSD cream (1%) vs biosynthetic dressing with skin substitute (Transcyte® on Biobrane® mesh), Outcome 1 Number of patients that developed wound infection.



Comparison 3. SSD cream (1%) with chlorhexidine-impregnated gauze (Bactigras®) vs hydrocolloid (Duoderm® Hydroactive)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	48	Risk Difference (M-H, Fixed, 95% CI)	-0.04 [-0.18, 0.09]

Analysis 3.1. Comparison 3 SSD cream (1%) with chlorhexidine-impregnated gauze (Bactigras®) vs hydrocolloid (Duoderm® Hydroactive), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD/Bacti-grass® n/N	Duoderm® HD n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Afilalo 1992	1/24	2/24		100%	-0.04[-0.18,0.09]
Total (95% CI)	**24**	**24**		**100%**	**-0.04[-0.18,0.09]**
Total events: 1 (SSD/Bactigrass®), 2 (Duoderm® HD)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.6(P=0.55)					



Comparison 4. SSD cream (1%) vs hydrocolloid (Duoderm® Hydroactive)

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	42	Risk Difference (M-H, Fixed, 95% CI)	0.0 [-0.09, 0.09]
2 Mean pain scores	1	42	Mean Difference (IV, Fixed, 95% CI)	1.19 [0.56, 1.82]

Analysis 4.1. Comparison 4 SSD cream (1%) vs hydrocolloid (Duoderm® Hydroactive), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Duoderm® HD n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Wyatt 1990	0/20	0/22		100%	0[-0.09,0.09]
Total (95% CI)	**20**	**22**		**100%**	**0[-0.09,0.09]**
Total events: 0 (SSD), 0 (Duoderm® HD)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					

Analysis 4.2. Comparison 4 SSD cream (1%) vs hydrocolloid (Duoderm® Hydroactive), Outcome 2 Mean pain scores.

Study or subgroup	SSD N	SSD Mean(SD)	Duoderm® HD N	Duoderm® HD Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
Wyatt 1990	20	2.3 (1.4)	22	1.1 (0.1)		100%	1.19[0.56,1.82]
Total ***	**20**		**22**			**100%**	**1.19[0.56,1.82]**
Heterogeneity: Not applicable							
Test for overall effect: Z=3.71(P=0)							

Comparison 5. SSD cream (1%) vs honey

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients with clinical evidence of wound infection	1		Risk Difference (M-H, Fixed, 95% CI)	Totals not selected
1.1 Day 7	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Day 21	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Number of wounds completely healed	1		Risk Difference (M-H, Fixed, 95% CI)	Totals not selected
2.1 week 2	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 week 4	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.3 week 6	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Number of patients with clinical evidence of wound healing (day 21)	1	50	Risk Difference (M-H, Fixed, 95% CI)	-0.16 [-0.31, -0.01]
4 Number of patients reporting free of pain	1		Risk Difference (M-H, Fixed, 95% CI)	Totals not selected
4.1 week 1	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 week 2	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.3 week 3	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.4 week 4	1		Risk Difference (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Analysis 5.1. Comparison 5 SSD cream (1%) vs honey, Outcome 1 Number of patients with clinical evidence of wound infection.

Study or subgroup	SSD n/N	Honey n/N	Risk Difference M-H, Fixed, 95% CI	Risk Difference M-H, Fixed, 95% CI
5.1.1 Day 7				
Subrahmanyam 1998	2/25	2/25		0[-0.15,0.15]
5.1.2 Day 21				
Subrahmanyam 1998	5/25	0/25		0.2[0.03,0.37]



Analysis 5.2. Comparison 5 SSD cream (1%) vs honey, Outcome 2 Number of wounds completely healed.

Study or subgroup	SSD n/N	Honey n/N	Risk Difference M-H, Fixed, 95% CI	Risk Difference M-H, Fixed, 95% CI
5.2.1 week 2				
Mashhood 2006	5/25	13/25		-0.32[-0.57,-0.07]
5.2.2 week 4				
Mashhood 2006	15/25	25/25		-0.4[-0.6,-0.2]
5.2.3 week 6				
Mashhood 2006	25/25	25/25		0[-0.07,0.07]



Analysis 5.3. Comparison 5 SSD cream (1%) vs honey, Outcome 3 Number of patients with clinical evidence of wound healing (day 21).

Study or subgroup	SSD n/N	Honey n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Subrahmanyam 1998	21/25	25/25		100%	-0.16[-0.31,-0.01]
Total (95% CI)	**25**	**25**		**100%**	**-0.16[-0.31,-0.01]**
Total events: 21 (SSD), 25 (Honey)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.03(P=0.04)					



Analysis 5.4. Comparison 5 SSD cream (1%) vs honey, Outcome 4 Number of patients reporting free of pain.

Study or subgroup	SSD n/N	Honey n/N	Risk Difference M-H, Fixed, 95% CI	Risk Difference M-H, Fixed, 95% CI
5.4.1 week 1				
Mashhood 2006	4/25	9/25		-0.2[-0.44,0.04]
5.4.2 week 2				
Mashhood 2006	11/25	20/25		-0.36[-0.61,-0.11]
5.4.3 week 3				
Mashhood 2006	18/25	25/25		-0.28[-0.46,-0.1]
5.4.4 week 4				
Mashhood 2006	25/25	25/25		0[-0.07,0.07]



Comparison 6. SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	86	Risk Difference (M-H, Fixed, 95% CI)	0.0 [-0.04, 0.04]
2 Number of patients with adverse effects	1	86	Risk Difference (M-H, Fixed, 95% CI)	0.02 [-0.05, 0.10]
3 Number of patients reporting wound pain	1	86	Risk Difference (M-H, Fixed, 95% CI)	-0.02 [-0.16, 0.12]

Analysis 6.1. Comparison 6 SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine, Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Liposome HG PVP-I n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Homann 2007	0/43	0/43		100%	0[-0.04,0.04]
Total (95% CI)	**43**	**43**		**100%**	**0[-0.04,0.04]**
Total events: 0 (SSD), 0 (Liposome HG PVP-I)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					



Analysis 6.2. Comparison 6 SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine, Outcome 2 Number of patients with adverse effects.

Study or subgroup	SSD n/N	Liposome HG PVP-I n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Homann 2007	2/43	1/43		100%	0.02[-0.05,0.1]
Total (95% CI)	**43**	**43**		**100%**	**0.02[-0.05,0.1]**
Total events: 2 (SSD), 1 (Liposome HG PVP-I)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.59(P=0.56)					



Analysis 6.3. Comparison 6 SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine, Outcome 3 Number of patients reporting wound pain.

Study or subgroup	SSD n/N	Liposome HG PVP-I n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Homann 2007	5/43	6/43		100%	-0.02[-0.16,0.12]
Total (95% CI)	**43**	**43**		**100%**	**-0.02[-0.16,0.12]**
Total events: 5 (SSD), 6 (Liposome HG PVP-I)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.32(P=0.75)					

Comparison 7. SSD cream (1%) vs collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®)

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	158	Risk Difference (M-H, Fixed, 95% CI)	-0.01 [-0.12, 0.10]
2 Number of patients reporting pain	1	158	Risk Difference (M-H, Fixed, 95% CI)	-0.19 [-0.31, -0.07]

Analysis 7.1. Comparison 7 SSD cream (1%) vs collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Santyl® Col-lagenase n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Hansbrough 1995	11/79	12/79		100%	-0.01[-0.12,0.1]
Total (95% CI)	**79**	**79**		**100%**	**-0.01[-0.12,0.1]**
Total events: 11 (SSD), 12 (Santyl® Collagenase)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.23(P=0.82)					



Analysis 7.2. Comparison 7 SSD cream (1%) vs collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®), Outcome 2 Number of patients reporting pain.

Study or subgroup	SSD n/N	Santyl® Col-lagenase n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Hansbrough 1995	9/79	24/79		100%	-0.19[-0.31,-0.07]
Total (95% CI)	**79**	**79**		**100%**	**-0.19[-0.31,-0.07]**





Comparison 8. SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients with positive cultures (day 10)	1	64	Risk Difference (M-H, Fixed, 95% CI)	0.38 [0.17, 0.58]
2 Number of wounds completely healed	1	64	Risk Difference (M-H, Fixed, 95% CI)	-0.16 [-0.34, 0.02]
3 Number of patients reporting moderate to severe pain	1	64	Risk Difference (M-H, Fixed, 95% CI)	0.31 [0.09, 0.54]

Analysis 8.1. Comparison 8 SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin), Outcome 1 Number of patients with positive cultures (day 10).



Analysis 8.2. Comparison 8 SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin), Outcome 2 Number of wounds completely healed.



Analysis 8.3. Comparison 8 SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin), Outcome 3 Number of patients reporting moderate to severe pain.

Study or subgroup	SSD n/N	Phenytoin n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Carneiro 2002	17/32	7/32		100%	0.31[0.09,0.54]
Total (95% CI)	**32**	**32**		**100%**	**0.31[0.09,0.54]**
Total events: 17 (SSD), 7 (Phenytoin)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.73(P=0.01)					



Comparison 9. Nanocrystalline silver-coated dressing (Acticoat®) vs hydrophilic polyurethane dressing (Allevyn®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	32	Risk Difference (M-H, Fixed, 95% CI)	0.0 [-0.11, 0.11]
2 Number of wounds healed by day of discharge	1	32	Risk Difference (M-H, Fixed, 95% CI)	-0.69 [-0.92, -0.45]

Analysis 9.1. Comparison 9 Nanocrystalline silver-coated dressing (Acticoat®) vs hydrophilic polyurethane dressing (Allevyn®), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	Acticoat® n/N	Allevyn® n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Innes 2001	0/16	0/16		100%	0[-0.11,0.11]
Total (95% CI)	**16**	**16**		**100%**	**0[-0.11,0.11]**
Total events: 0 (Acticoat®), 0 (Allevyn®)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					



Analysis 9.2. Comparison 9 Nanocrystalline silver-coated dressing (Acticoat®) vs hydrophilic polyurethane dressing (Allevyn®), Outcome 2 Number of wounds healed by day of discharge.

Study or subgroup	Acticoat® n/N	Allevyn® n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Innes 2001	5/16	16/16		100%	-0.69[-0.92,-0.45]





Comparison 10. Silver nitrate (0.5%) vs Ringer's lactate

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	34	Risk Difference (M-H, Fixed, 95% CI)	-0.43 [-0.72, -0.14]

Analysis 10.1. Comparison 10 Silver nitrate (0.5%) vs Ringer's lactate, Outcome 1 Number of patients that developed wound infection.



Comparison 11. Silver nitrate (0.5%) vs neomycin with bacitracin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	37	Risk Difference (M-H, Fixed, 95% CI)	-0.23 [-0.49, 0.03]

Analysis 11.1. Comparison 11 Silver nitrate (0.5%) vs neomycin with bacitracin, Outcome 1 Number of patients that developed wound infection.





Comparison 12. SSD/SILVER vs NO SILVER

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	10		Risk Difference (M-H, Random, 95% CI)	Subtotals only

Analysis 12.1. Comparison 12 SSD/SILVER vs NO SILVER, Outcome 1 Number of patients that developed wound infection.



Comparison 13. SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	50	Risk Difference (M-H, Fixed, 95% CI)	0.04 [-0.15, 0.23]
2 Mean background pain scores	1	50	Mean Difference (IV, Fixed, 95% CI)	1.0 [0.64, 1.36]
3 Mean length of hospital stay	1	50	Mean Difference (IV, Fixed, 95% CI)	0.0 [-6.43, 6.43]

Analysis 13.1. Comparison 13 SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®), Outcome 1 Number of patients that developed wound infection.



Analysis 13.2. Comparison 13 SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®), Outcome 2 Mean background pain scores.



Analysis 13.3. Comparison 13 SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®), Outcome 3 Mean length of hospital stay.



Comparison 14. SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag)

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	82	Risk Difference (M-H, Fixed, 95% CI)	-0.04 [-0.20, 0.12]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Number of patients with re-epithelialisation within 21 days	1	82	Risk Difference (M-H, Fixed, 95% CI)	-0.14 [-0.34, 0.06]
3 Number of patients reporting adverse effects	1	82	Risk Difference (M-H, Fixed, 95% CI)	-0.03 [-0.24, 0.19]
4 Number of patients using systemic antibiotics	1	82	Risk Difference (M-H, Fixed, 95% CI)	-0.04 [-0.20, 0.12]
5 Total costs of clinical care (USD)	1	82	Mean Difference (IV, Fixed, 95% CI)	140.80 [-216.12, 497.72]

Analysis 14.1. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Aquacel® Ag n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Caruso 2006	6/40	8/42		100%	-0.04[-0.2,0.12]
Total (95% CI)	**40**	**42**		**100%**	**-0.04[-0.2,0.12]**
Total events: 6 (SSD), 8 (Aquacel® Ag)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.49(P=0.63)					

Analysis 14.2. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 2 Number of patients with re-epithelialisation within 21 days.

Study or subgroup	SSD n/N	Aquacel® Ag n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Caruso 2006	24/40	31/42		100%	-0.14[-0.34,0.06]
Total (95% CI)	**40**	**42**		**100%**	**-0.14[-0.34,0.06]**
Total events: 24 (SSD), 31 (Aquacel® Ag)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.34(P=0.18)					



Analysis 14.3. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 3 Number of patients reporting adverse effects.



Analysis 14.4. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 4 Number of patients using systemic antibiotics.



Analysis 14.5. Comparison 14 SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag), Outcome 5 Total costs of clinical care (USD).



Comparison 15. SSD cream (1%) vs synthetic dressing containing silver (Hydron AgSD (1-3%))

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients with positive cultures	1	196	Risk Difference (M-H, Fixed, 95% CI)	0.14 [0.01, 0.28]

Analysis 15.1. Comparison 15 SSD cream (1%) vs synthetic dressing containing silver (Hydron AgSD (1-3%)), Outcome 1 Number of patients with positive cultures.

Study or subgroup	SSD n/N	Hydron AgSD n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Fang 1987	46/98	32/98		100%	0.14[0.01,0.28]
Total (95% CI)	**98**	**98**		**100%**	**0.14[0.01,0.28]**
Total events: 46 (SSD), 32 (Hydron AgSD)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.07(P=0.04)					



Comparison 16. SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	121	Risk Difference (M-H, Fixed, 95% CI)	-0.01 [-0.14, 0.13]
2 Number of patients that received antibiotics	1	121	Risk Difference (M-H, Fixed, 95% CI)	0.10 [-0.03, 0.24]
3 Number of patients reporting extreme pain at application	1	121	Risk Difference (M-H, Fixed, 95% CI)	-0.02 [-0.07, 0.03]

Analysis 16.1. Comparison 16 SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Silvazine® n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Inman 1984	12/67	10/54		100%	-0.01[-0.14,0.13]
Total (95% CI)	**67**	**54**		**100%**	**-0.01[-0.14,0.13]**
Total events: 12 (SSD), 10 (Silvazine®)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.09(P=0.93)					



Analysis 16.2. Comparison 16 SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®), Outcome 2 Number of patients that received antibiotics.

Study or subgroup	SSD n/N	Silvazine® n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Inman 1984	59/67	42/54		100%	0.1[-0.03,0.24]



Analysis 16.3. Comparison 16 SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®), Outcome 3 Number of patients reporting extreme pain at application.



Comparison 17. SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Sepsis after 10 days	1	60	Risk Difference (M-H, Fixed, 95% CI)	0.1 [-0.02, 0.22]
2 Number of patients reporting subjective stinging effect	1	60	Risk Difference (M-H, Fixed, 95% CI)	-0.37 [-0.58, -0.15]
3 Number of patients receiving systemic antibiotics for at least 7 days	1	60	Risk Difference (M-H, Fixed, 95% CI)	-0.03 [-0.20, 0.13]
4 Mean length of hospital stay	1	60	Mean Difference (IV, Fixed, 95% CI)	7.40 [-1.69, 16.49]

Analysis 17.1. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 1 Sepsis after 10 days.





Analysis 17.2. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 2 Number of patients reporting subjective stinging effect.



Analysis 17.3. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 3 Number of patients receiving systemic antibiotics for at least 7 days.



Analysis 17.4. Comparison 17 SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®), Outcome 4 Mean length of hospital stay.



Comparison 18. SSD cream (1%) (Silvadene®) vs Dimac containing SSD (Sildimac®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed clinical wound sepsis	1	102	Risk Difference (M-H, Fixed, 95% CI)	0.02 [-0.05, 0.09]
2 Number of patients reporting local adverse effects	1	118	Risk Difference (M-H, Fixed, 95% CI)	0.03 [-0.10, 0.16]

Analysis 18.1. Comparison 18 SSD cream (1%) (Silvadene®) vs Dimac containing SSD (Sildimac®), Outcome 1 Number of patients that developed clinical wound sepsis.

Study or subgroup	SSD n/N	Sildimac® n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Miller 1990	2/51	1/51		100%	0.02[-0.05,0.09]
Total (95% CI)	**51**	**51**		**100%**	**0.02[-0.05,0.09]**
Total events: 2 (SSD), 1 (Sildimac®)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.59(P=0.56)					

Analysis 18.2. Comparison 18 SSD cream (1%) (Silvadene®) vs Dimac containing SSD (Sildimac®), Outcome 2 Number of patients reporting local adverse effects.

Study or subgroup	SSD n/N	Sildimac® n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Miller 1990	10/59	8/59		100%	0.03[-0.1,0.16]
Total (95% CI)	**59**	**59**		**100%**	**0.03[-0.1,0.16]**
Total events: 10 (SSD), 8 (Sildimac®)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.51(P=0.61)					



Comparison 19. Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	34	Risk Difference (M-H, Fixed, 95% CI)	-0.65 [-0.89, -0.40]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Number of patients that developed bacteraemia	1	34	Risk Difference (M-H, Fixed, 95% CI)	-0.24 [-0.48, 0.01]
3 Mean overall painscore	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.28 [-0.93, 0.37]

Analysis 19.1. Comparison 19 Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%), Outcome 1 Number of patients that developed wound infection.

Study or subgroup	Acticoat® n/N	FM silver nitrate n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Tredget 1998	5/17	16/17		100%	-0.65[-0.89,-0.4]
Total (95% CI)	**17**	**17**		**100%**	**-0.65[-0.89,-0.4]**
Total events: 5 (Acticoat®), 16 (FM silver nitrate)					
Heterogeneity: Not applicable					
Test for overall effect: Z=5.2(P<0.0001)					



Analysis 19.2. Comparison 19 Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%), Outcome 2 Number of patients that developed bacteraemia.

Study or subgroup	Acticoat® n/N	FM silver nitrate n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Tredget 1998	1/17	5/17		100%	-0.24[-0.48,0.01]
Total (95% CI)	**17**	**17**		**100%**	**-0.24[-0.48,0.01]**
Total events: 1 (Acticoat®), 5 (FM silver nitrate)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.89(P=0.06)					



Analysis 19.3. Comparison 19 Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%), Outcome 3 Mean overall painscore.

Study or subgroup	Acticoat® N	Acticoat® Mean(SD)	FM silver nitrate N	FM silver nitrate Mean(SD)	Mean Difference Fixed, 95% CI	Weight	Mean Difference Fixed, 95% CI
Tredget 1998	30	3.2 (1.3)	30	3.5 (1.3)		100%	-0.28[-0.93,0.37]
Total ***	**30**		**30**			**100%**	**-0.28[-0.93,0.37]**
Heterogeneity: Not applicable							
Test for overall effect: Z=0.84(P=0.4)							

Comparison 20. SSD cream (1%) vs bacitracin zinc ointment

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	208	Risk Difference (M-H, Fixed, 95% CI)	0.07 [-0.01, 0.14]

Analysis 20.1. Comparison 20 SSD cream (1%) vs bacitracin zinc ointment, Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Bacitracin zinc n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Dire 1995	12/99	6/109		100%	0.07[-0.01,0.14]
Total (95% CI)	**99**	**109**		**100%**	**0.07[-0.01,0.14]**
Total events: 12 (SSD), 6 (Bacitracin zinc)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.68(P=0.09)					

Comparison 21. SSD cream (1%) vs neomycin sulfate

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	209	Risk Difference (M-H, Fixed, 95% CI)	0.08 [0.00, 0.15]

Analysis 21.1. Comparison 21 SSD cream (1%) vs neomycin sulfate, Outcome 1 Number of patients that developed wound infection.

Study or subgroup	SSD n/N	Neomycin sulfate n/N	Risk Difference M-H, Fixed, 95% CI	Weight	Risk Difference M-H, Fixed, 95% CI
Dire 1995	12/99	5/110		100%	0.08[0,0.15]
Total (95% CI)	**99**	**110**		**100%**	**0.08[0,0.15]**
Total events: 12 (SSD), 5 (Neomycin sulfate)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.98(P=0.05)					



Comparison 22. SSD cream (1%) vs petrolatum

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	207	Risk Difference (M-H, Fixed, 95% CI)	-0.05 [-0.15, 0.04]

Analysis 22.1. Comparison 22 SSD cream (1%) vs petrolatum, Outcome 1 Number of patients that developed wound infection.



Comparison 23. Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	67	Risk Difference (M-H, Fixed, 95% CI)	-0.01 [-0.17, 0.14]
2 Number of wounds completely healed at end of treatment	1	67	Risk Difference (M-H, Fixed, 95% CI)	0.13 [-0.04, 0.31]
3 Number of patients that reported adverse effects	1	67	Risk Difference (M-H, Fixed, 95% CI)	-0.09 [-0.21, 0.02]

Analysis 23.1. Comparison 23 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze, Outcome 1 Number of patients that developed wound infection.



Analysis 23.2. Comparison 23 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze, Outcome 2 Number of wounds completely healed at end of treatment.



Analysis 23.3. Comparison 23 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze, Outcome 3 Number of patients that reported adverse effects.



Comparison 24. SSD cream (1%) vs benzoic acid, salicylic acid and *Quercus rubra* extract (Bensal HP)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of wounds healed (6 weeks)	1	40	Risk Difference (M-H, Fixed, 95% CI)	-0.10 [-0.39, 0.19]

Analysis 24.1. Comparison 24 SSD cream (1%) vs benzoic acid, salicylic acid and *Quercus rubra* extract (Bensal HP), Outcome 1 Number of wounds healed (6 weeks).



Comparison 25. Activated-charcoal dressing containing silver (Actisorb Plus®) vs conventional phase-adapted therapy using diverse topical modalities

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of wounds healed (6 weeks)	1	38	Risk Difference (M-H, Fixed, 95% CI)	0.21 [-0.04, 0.46]

Analysis 25.1. Comparison 25 Activated-charcoal dressing containing silver (Actisorb Plus®) vs conventional phase-adapted therapy using diverse topical modalities, Outcome 1 Number of wounds healed (6 weeks).



Comparison 26. Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	134	Risk Difference (M-H, Fixed, 95% CI)	0.04 [-0.07, 0.16]
2 Time to complete healing	1	134	Mean Difference (IV, Fixed, 95% CI)	-5.10 [-5.69, -4.51]
3 Number of wounds completely healed during study	1	134	Risk Difference (M-H, Fixed, 95% CI)	0.09 [-0.06, 0.24]
4 Percentage ulcer area reduction in 8 weeks	1	134	Mean Difference (IV, Fixed, 95% CI)	-2.40 [-18.72, 13.92]
5 Ulcer depth reduction in 8 weeks (cm)	1	100	Mean Difference (IV, Fixed, 95% CI)	0.12 [-0.05, 0.29]
6 Number of patients that experienced adverse effects	1	134	Risk Difference (M-H, Fixed, 95% CI)	-0.01 [-0.18, 0.15]

Analysis 26.1. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 1 Number of patients that developed wound infection.



Analysis 26.2. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 2 Time to complete healing.



Analysis 26.3. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 3 Number of wounds completely healed during study.



Analysis 26.4. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 4 Percentage ulcer area reduction in 8 weeks.





Analysis 26.5. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 5 Ulcer depth reduction in 8 weeks (cm).



Analysis 26.6. Comparison 26 Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®), Outcome 6 Number of patients that experienced adverse effects.



Comparison 27. SSD cream (1%)/hydrocolloid vs hydrocolloid

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	166	Risk Difference (M-H, Fixed, 95% CI)	-0.02 [-0.06, 0.02]

Analysis 27.1. Comparison 27 SSD cream (1%)/hydrocolloid vs hydrocolloid, Outcome 1 Number of patients that developed wound infection.





Comparison 28. SSD cream (1%)/hydrocolloid vs non-occlusive paraffin-impregnated gauze

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Number of patients that developed wound infection	1	184	Risk Difference (M-H, Fixed, 95% CI)	-0.06 [-0.10, -0.01]

Analysis 28.1. Comparison 28 SSD cream (1%)/hydrocolloid vs non-occlusive paraffin-impregnated gauze, Outcome 1 Number of patients that developed wound infection.



APPENDICES

Appendix 1. Ovid MEDLINE Search Strategy

1 exp Wound Infection/
2 (wound$ adj5 infect$).mp.
3 or/1-2
4 exp Skin Ulcer/
5 exp Diabetic Foot/
6 exp Pressure Ulcer/
7 exp Wounds, Penetrating/
8 exp Lacerations/
9 exp Burns/
10 exp "Bites and Stings"/
11 exp Surgical Wound Dehiscence/
12 exp Wound Healing/
13 (skin ulcer$ or foot ulcer$ or (feet adj5 ulcer$) or diabetic foot or diabetic ulcer$ or leg ulcer$ or varicose ulcer$ or (varicose adj5 wound $) or venous ulcer$ or stasis ulcer$ or arterial ulcer$).mp.
14 ((ischaemic or ischemic) adj (wound$ or ulcer$)).mp.
15 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).mp.

16 surgical wound$.mp.
17 (gun or guns or gunshot).mp.
18 (stab or stabs or stabbing).mp.
19 (burn or burns or scald$).ti,ab.
20 (bite or bites or biting).mp.
21 laceration$.mp.
22 or/4-21
23 (infect$ or swell$ or swollen or erythema$ or odour or odor or hypertherm$ or coloni$ or contamin$ or inflamm$ or purulent or exudat$ or devital$).mp.
24 (positive adj5 culture$).mp.
25 (pain$ adj5 wound$).mp.
26 (dirty adj5 wound$).mp.
27 or/23-26
28 exp Silver/
29 (silver$ or contreet or acticoat or aquacel or avance or argent$ or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina).mp. (49935)
30 or/28-29
31 22 and 27 and 30
32 3 and 30
33 or/31-32

Appendix 2. Ovid EMBASE Search Strategy

1 exp Wound Infection/
2 (wound$ adj5 infect$).mp.
3 or/1-2
4 exp Skin Ulcer/
5 exp Diabetic Foot/
6 exp Decubitus/
7 exp Penetrating Trauma/
8 exp Laceration/
9 exp Burn/
10 exp Bite Wound/
11 exp Surgical Wound/
12 exp Wound Healing/
13 (skin ulcer$ or foot ulcer$ or (feet adj5 ulcer$) or diabetic foot or diabetic ulcer$ or leg ulcer$ or varicose ulcer$ or (varicose adj5 wound$) or venous ulcer$ or stasis ulcer$ or arterial ulcer$).mp.
14 ((ischaemic or ischemic) adj (wound$ or ulcer$)).mp.
15 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).mp.
16 surgical wound$.mp.
17 (gun or guns or gunshot).mp.
18 (stab or stabs or stabbing).mp.
19 (burn or burns or scald$).ti,ab.
20 (bite or bites or biting).mp.
21 laceration$.mp.
22 or/4-21
23 (infect$ or swell$ or swollen or erythema$ or odour or odor or hypertherm$ or coloni$ or contamin$ or inflamm$ or purulent or exudat$ or devital$).mp.
24 (positive adj5 culture$).mp.
25 (pain$ adj5 wound$).mp.
26 (dirty adj5 wound$).mp.
27 or/23-26
28 exp Silver/
29 (silver$ or contreet or acticoat or aquacel or avance or argent$ or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina).mp. (41820)
30 or/28-29
31 22 and 27 and 30
32 3 and 30

33 or/31-32

Appendix 3. EBSCO CINAHL Search Strategy

S34 S32 or S33
S33 S3 and S31
S32 S22 and S27 and S31
S31 S28 or S29 or S30
S30 TI (silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina) or AB (silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina)TI (silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina) or AB (silver* or contreet or acticoat or aquacel or avance or argent* or CuNo ...Show Less
S29 (MH "Silver Sulfadiazine")
S28 (MH "Silver")
S27 S23 or S24 or S25 or S26
S26 TI dirty N5 wound* or AB dirty N5 wound*
S25 TI pain* N5 wound* or AB pain* N5 wound*
S24 TI positive N5 culture* or AB positive N5 culture*
S23 TI (infect* or swell* or swollen or erythema* or odour or odor or hypertherm* or coloni* or contamin* or inflamm* or purulent or exudat* or devital*) or AB (infect* or swell* or swollen or erythema* or odour or odor or hypertherm* or coloni* or contamin* or inflamm* or purulent or exudat* or devital*)
S22 S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21
S21 TI surgical wound* or AB surgical wound*
S20 TI laceration* or AB laceration*
S19 TI (bite or bites or biting) or AB (bite or bites or biting)
S18 TI (burn or burns or scald*) or AB (burn or burns or scald*)
S17 TI (stab or stabs or stabbing) or AB (stab or stabs or stabbing)
S16 TI (gun or guns or gunshot) or AB (gun or guns or gunshot)
S15 TI (bed sore* or pressure sore* or pressure ulcer* or decubitus) or AB (bed sore* or pressure sore* or pressure ulcer* or decubitus)
S14 TI (ischaemic wound* or ischemic wound* or ischaemic ulcer* or ischemic ulcer*) or AB (ischaemic wound* or ischemic wound* or ischaemic ulcer* or ischemic ulcer*)
S13 TI (skin ulcer* or foot ulcer* or diabetic foot or diabetic ulcer* or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or arterial ulcer*) or AB (skin ulcer* or foot ulcer* or diabetic foot or diabetic ulcer* or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or arterial ulcer*)
S12 (MH "Wound Healing+")
S11 (MH "Surgical Wound Care+")
S10 (MH "Surgical Wound Dehiscence")
S9 (MH "Surgical Wound")
S8 (MH "Bites and Stings+")
S7 (MH "Burns+")
S6 (MH "Tears and Lacerations")
S5 (MH "Wounds, Penetrating+")
S4 (MH "Skin Ulcer+")
S3 S1 or S2
S2 TI wound* N5 infect* or AB wound* N5 infect*
S1 (MH "Wound Infection+")

Appendix 4. Risk of bias descriptors for the domains

Criteria for judgements

1. Was the allocation sequence randomly generated?

Yes, low risk of bias

A random (unpredictable) assignment sequence.

Examples of adequate methods of sequence generation include computer-generated random sequence, pre-ordered sealed envelopes, telephone call to a central office, coin toss (for studies with two groups), rolling a dice (for studies with two or more groups), and drawing of balls of different colours.

No, high risk of bias

Quasi-randomised approach

Examples of inadequate methods include: alternation, birth date, social insurance/security number, date on which invited to participate in the study, and hospital registration number.

Non-random approaches

Allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.

Unclear

Insufficient information about the sequence generation process provided to permit judgement.

2. Was the treatment allocation adequately concealed?

Yes, low risk of bias

Assignment must be generated independently by a person who is not responsible for determining the eligibility of the participants. This person has no information about the people included in the trial and has no influence on either the assignment sequence, or the decision about whether a person is eligible to enter the trial. Examples of adequate methods of allocation concealment include: central allocation - including telephone, web-based, and pharmacy-controlled randomization; sequentially-numbered drug containers of identical appearance; and sequentially-numbered, opaque, sealed envelopes.

No, high risk of bias

Examples of inadequate methods of allocation concealment include: alternate medical record numbers, unsealed envelopes; dates of birth; case record numbers; alternation or rotation; an open list of random numbers; or any information in the study that indicates that investigators or participants could influence the intervention group.

Unclear

Randomisation stated but no available information on method of allocation used.

3. Blinding: was knowledge of the allocated interventions adequately prevented during the study?

Was the participant blinded to the intervention?

Yes, low risk of bias

The treatment and control groups were indistinguishable for the participants, or, if the participant was described as blinded, the method of blinding was described.

No, high risk of bias

Blinding of study participants attempted, but likely that the blinding could have been broken; participants not blinded, and the nonblinding of others likely to introduce bias.

Unclear

Insufficient information provided to permit judgement.

Was the care provider blinded to the intervention?

Yes, low risk of bias

The treatment and control groups were indistinguishable for the care/treatment providers, or, if the care provider was described as blinded, the method of blinding was described.

No, high risk of bias

Blinding of care/treatment providers attempted, but likely that the blinding could have been broken; care/treatment providers not blinded, and the nonblinding of others likely to introduce bias.

Unclear

Insufficient information provided to permit judgement

Was the outcome assessor blinded to the intervention?

Yes, low risk of bias

Adequacy of blinding should be assessed for the primary outcomes. The outcome assessor was described as blinded and the method of blinding was described.

No, high risk of bias

No blinding or incomplete blinding, and the outcome or outcome measurements were likely to be influenced by lack of blinding

Unclear

Insufficient information provided to permit judgement

4. Were incomplete outcome data adequately addressed?

Was the drop-out rate described and acceptable?

The number of participants who were included in the study but did not complete the observation period or were not included in the analysis must be described and reasons given for their non-completion.

Yes, low risk of bias

If the percentage of withdrawals and drop-outs does not exceed 20% for short-term follow-up and 30% for long-term follow-up, and does not lead to substantial bias (NB these percentages are arbitrary, i.e. not supported by literature); no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; and missing data have been imputed using appropriate methods.

No, high risk of bias

Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.

Unclear

Insufficient information provided to permit judgement

Were all randomised participants analysed in the group to which they were allocated? (ITT analysis)

Yes, low risk of bias

Specifically reported by authors that intention-to-treat (ITT) analysis was undertaken and this was confirmed on study assessment, or not stated, but evident from study assessment that all randomised participants were reported/analysed in the group to which they were allocated for the most important time point of outcome measurement (minus missing values) irrespective of non-compliance and co-interventions.

No, high risk of bias

Lack of ITT confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, withdrew from the study or violated the protocol) regardless of whether ITT reported or not.
'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomisation; or potentially inappropriate application of simple imputation.

Unclear

Described as ITT analysis, but unable to confirm on study assessment, or not reported, and unable to confirm by study assessment.

5. Other sources of potential bias:

Was the trial free from sponsorship by a manufacturer who potentially had an interest in the results?

Trials that state they received funding from a manufacturer or company with a direct interest in the intervention, or trialists funded or employed by a manufacturer or company with a direct interest in the intervention.

Were the groups similar at baseline regarding the most important prognostic indicators?

Groups should be similar at baseline for demographic factors, duration and severity of complaints, e.g. size and duration of ulcer. Alternatively, if there were imbalances at baseline that have been accounted for in the analysis of the study.

Were co-interventions avoided or similar?

There were no co-interventions or there were co-interventions but they were similar between the treatment and control groups.

HISTORY

Protocol first published: Issue 4, 2007
Review first published: Issue 3, 2010

Date	Event	Description
18 May 2008	Amended	Converted to new review format.
15 May 2008	New search has been performed	Substantive amendment
30 January 2007	New citation required and conclusions have changed	protocol published

CONTRIBUTIONS OF AUTHORS

Marja N Storm-Versloot

- Co-ordinated the review.
- Extracted and checked data and performed the statistical analysis.
- Undertook and checked the quality assessment.
- Analysed and interpreted the data.
- Completed the first draft of the review and contributed to the writing and editing of further drafts.
- Made an intellectual contribution to the review.
- Performed previous work that was the foundation of the current review and approved the final review prior to submission

Cornelis G Vos

- Extracted and checked data and performed the statistical analysis.
- Undertook and checked the quality assessment.
- Analysed and interpreted the data.
- Contributed to the writing and editing of the review.
- Wrote to study author, experts, and companies.
- Performed previous work that was the foundation of the current review and approved the final review prior to submission.

Dirk T Ubbink

- Conceived, designed and coordinated the review.
- Checked data extraction.
- Undertook and checked the quality assessment.
- Analysed and interpreted the data.
- Contributed to the writing and editing of the review and made an intellectual contribution to the review.
- Performed previous work that was the foundation of the current review and approved the final review prior to submission

Hester Vermeulen

- Conceived, designed and co-ordinated the review.
- Checked data extraction and quality assessment.
- Analysed and interpreted the data.

- Contributed to the writing and editing of the review and made an intellectual contribution to the review.
- Performed previous work that was the foundation of the current review and approved the final review prior to submission.

Contributions of editorial base

Nicky Cullum

- Edited the review, advised on methodology, interpretation and review content.
- Approved the final review prior to submission.

Sally Bell-Syer

- Co-ordinated the editorial process.
- Advised on methodology, interpretation and content.
- Edited the review.

Ruth Foxlee

- Designed the search strategy, ran the searches and edited the search methods and reference sections.

DECLARATIONS OF INTEREST

None

SOURCES OF SUPPORT

Internal sources

- Academic Medical Center; Amsterdam, Netherlands.

External sources

- No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We have added 'promoting healing' to the objective, indicating that the wound is not infected. Therefore the primary outcomes have been changed accordingly. A priori we did not identify time to grafting as an outcome, but in severe burns the goal is to prevent infection by grafting the wound as soon as possible. Therefore we have added time to grafting as it is a subjective indication of healing in the sense that the wound has become clean and is granulating, and thus ready for secondary closure. Study selection was based on one of these primary outcomes. Duration of wound infection was deleted, because this endpoint suggests treating an infected wound rather than preventing infection.

We planned to conduct subgroup analysis for each wound type. Due to the few studies identified for wound types other than burns, we categorised these wounds as acute, chronic or mixed wounds in order to evaluate the studies.

The search strategy was refined after consulting the Wounds Group Trial Search Co-ordinator.

INDEX TERMS

Medical Subject Headings (MeSH)

Administration, Topical; Bandages; Randomized Controlled Trials as Topic; Silver Compounds [*therapeutic use]; Silver Nitrate [therapeutic use]; Silver Sulfadiazine [therapeutic use]; Wound Infection [*prevention & control]

MeSH check words

Humans